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ABSTRACT
Tolerance-based stem cell transplantation using sub-lethal conditioning is being
considered for the treatment of human disease, but safety and efficacy remain to be
established. In order to study these two issues, we first established that mouse bone
marow recipients treated with sub-lethal irradiation plus transient blockade of the CD40-
CD154 costimulatory pathway develop permanent hematopoietic chimerism across
allogeneic barers. Our conditioning regimen of 6 Gy irradiation, a short course of anti-
CD154 mAb and 25 millon fully allogeneic BALB/c bone marow cells consistently
produced long-term stable, and multilineage chimerism in C57BL/6 recipients.
Furthermore, chimeric mice displayed donor-specific transplantation tolerance, as
BALB/c skin allografts were permanently accepted while third-pary CBA/JCr skin
allografts were promptly rejected. We next determned both the safety and efficacy of this
protocol by infecting chimeric mice with lymphocytic choriomeningitis virus (LCMV)
either at the time of transplantation or at several time points afterwards. Infection with
LCMV at the time of transplantation prevented engraftment of allogeneic, but not
syngeneic, bone marow in similarly treated mice. Surprisingly, infected allograft
recipients also failed to clear the virus and died. Post-mortem study revealed hypoplastic
bone marow and spleens. Hypoplasia and death in these mice required the combination
of 6 Gy irradiation, LCMV infection on the day of transplantation, and an allogeneic
bone marow transplant but did not require the presence of anti-CDl54 mAb.
Allochimeric mice infected with LCMV 15 days after transplantation were able to
survive and maintain their bone marow graft, indicating that the deleterious effects of
LCMV infection on host and graft survival are confined to a narow window of time
during the tolerization and transplantation process. The final section of this thesis studied
the mechanisms of graft rejection and death in sublethally irradiated recipients of
allogeneic bone marow and infection with LCMV at the time of bone marow
transplantation. Infection of interferon-a/j3 receptor knockout mice at the time of
transplantation prevented the engraftment of allogeneic bone marow, but the mice
survived. Therefore, IF-aj3 is involved in the development of marow hypoplasia and
death, whereas a second mechanism is involved in blocking the development of
chimerism in these mice. Through the use of depleting mAb' s and knockout mice we
demonstrate that three types of recipients survived and became chimeric after being given
sublethal irradiation, anti-CDl54 mAb, an allogeneic bone marow transplant and a day 0
LCMV infection: mice depleted of CD8+ T cells, CD8 knockout mice, and TCR-aj3
knockout mice. Our data indicate that the mediator of bone marow allograft destrction
in LCMV -infected mice treated with costimulatory blockade is a radioresistant CD8+
NKl. l- TCRaj3+ T cell. We conclude that a non-cytopathic viral infection at the time of
transplantation can prevent engraftment of allogeneic bone marow and result in the death
of sub-lethally irradiated mice treated with co stimulation blockade. The abrogation of
allogeneic bone marow engraftment is mediated by a population of CD8+ NKl.
TCRaj3+ T cells and the mediator of hypoplasia and death is viral induction of IF-aj3.
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ABBREVIA TIONS
MP, 6-mercaptopurine
ADCC, antibody-dependent cell-mediated cytotoxicity
APCs, antigen-presenting cells
AZA, azathioprine
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CTL, cytotoxic T lymphocytes
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DLA, dog leukocyte antigen
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I-- INTRODUCTION
Human hematopoietic stem cell (HSC) transplantation has required lethal whole
body irradiation and immunosuppression. Although these conditioning regimens have
permitted stem cell engraftment while successfully lowering the incidence of rejection
there are a number of side effects associated with this therapy. The use of lethal
conditioning and chronic immunosuppression leads to a state of severe neutropenia as
well as a prolonged suppression of T and B cell function (1). As a result, patients are
predisposed to a varety of bacterial, fungal and viral infections as well as neoplasia.
Although immunosuppression can prevent acute graft-versus-host disease (GVHD), it
cannot prevent chronic GVHD (1). Additionally, the requirement for lethal irradiation
restrcts this form of transplantation to those patients who suffer from lethal malignancies
or hematological diseases. Finally, stem cell transplantation using lethal irradiation
typically produces a state of full donor chimerism.
In order to overcome these problems, newer approaches to hematopoietic stem
cell transplantation have focused on less toxic approaches, paricularly sublethal
conditioning regimens that do not rely on the use of chronic immunosuppression. These
approaches have also focused on creating mixed hematopoietic chimeras, a state in which
both donor and host cells co-exist in the recipient. The presence of a mixed chimera has
several advantages over complete donor chimerism including improved immune
reactivity (2) and a decrease in the likelihood of GVHD (3). Additionally, the use of
sublethal conditioning could allow stem cell transplantation to be used as a realistic
option for non-lethal malignancies, autoimmune disease and organ transplantation.
One approach to induce hematopoietic chimerism is the use of costimulation
blockade. Costimulation blockade of T cell activation has been found to induce potent
donor-specific non-responsiveness and
, in the case of hematopoietic stem cell
transplantation, facilitates the engraftment and establishment of allogeneic hematopoietic
chimerism (4). This approach has been used to successfully establish hematopoietic
chimeras in mice, while also significantly reducing the toxicity of the conditioning
regimens (4).
Unfortunately, the safety and efficacy of protocols based on costimulation
blockade and sublethal conditioning to create hematopoietic chimerism has not yet been
well studied, paricularly with respect to viral infection. Viral induction of inflammatory
cytokines, T cell growth and differentiation factors as well as virus-specific CTL that
react to allogeneic targets (5) could potentially compromise graft survival. Further
, many
viruses can enhance GVHD after bone marow transplantation (6). Finally, patients
treated with parial myeloablation combined with costimulation blockade could be less
resistant to viral infection and its associated pathophysiological effects.
The goal of this thesis research was to determne the safety and efficacy of
allogeneic hematopoietic stem cell transplantation based on costimulation blockade and
sublethal irradiation. In paricular, this thesis focused on the abilty of LCMV infection to
abrogate either the initiation or maintenance of hematopoietic chimerism and donor-
specific transplantation tolerance.
1. History of Transplantation
A. Incons icuous be innin
Although Sir Peter Medewar is largely credited with establishing the field of
modern transplantation biology in the 1960s
, legends of successful transplantation can be
traced as far back as SOO B.C. It was during this time that the Indian surgeon Susrata
described methods for replacing amputated noses
, a common punishment for crimes
, with
skin flaps from the criminals
' cheeks (7, S). Two other famous legends relating to
transplantation occurred during the first few centures. According to Chinese legend
, the
physician Pien Ch' iao exchanged the hears of two men with opposite personalities in
order to restore the Yin and Yang balance between them (9). A second legend called the
miracle of the black leg
, tells how the Saints Cosmas and Damian 
replaced the
gangrenous leg of the Roman deacon Justinian with one taken from an Ethiopian Moor
who had recently died (10). Justinian supposedly woke up and walked away with his
healthy black leg the very next day.
In the 16th century Gaspare Tagliocozzi perfected the nose replacement
techniques of Susrata. Instead of using cheek skin he 
typically transplanted skin from
patients ' ars to re-create their noses (11). Interestingly, he was the first person to
acknowledge the difficulties of transplanting between people and associated this problem
to the "biochemical individuality
" of people (11).
Many other cases of successful autografts (transplantation from one location on a
patient's body to another location on the same patient) were reported in the 17
and ISth
centuries. However
, as opposed to the success seen with autografts
, transplantation from
one individual of a species to another individual of that species (allografts) universally
failed. George Schone reviewed the status of transplantation research in the early 1900s
and summarzed the information in his "laws of transplantation" (12). These laws stated:
1. Transplantation into a foreign species invarably fails.
2. Transplantation into unrelated members of the same species usually
fails.
3. Autografts almost invarably succeed.
4. There is a primary take and then delayed rejection of the first graft into
an unrelated member of the same species.
5. There is accelerated rejection of a second graft in a recipient that had
previously rejected a graft from the same donor, or of a first graft in a
recipient that had been pre-immunized with material from the same donor.
6. The closer the "blood relationship" between donor and recipient, the
more likely is graft success.
B. Groundbreakn discoveries
Four discoveries in the first half of the 20 century helped to elucidate the puzzle
of allograft rejection and improve the techniques involved in transplantation. In 1900
Landsteiner noted that serum from certain individuals caused agglutination of red blood
cells from other individuals (13). Twenty-five years later, this work led to the
identification of the ABO blood group system, and the discovery that blood transfusions
within the same blood group succeeded whereas transfusions between different groups
failed (14).
A second major discovery was made in 1912 by the French surgeon Alexis Carel
who pioneered the method of joining blood vessels together, enabling surgeons to
perform organ transplantation for the first time (15). The third discovery was made in
1948 by Gorer, Lyman and Snell who described a single dominant locus in mice that was
responsible for either the acceptance or rejection of transplanted tissues (16). This locus
would eventually be called the major histocompatibility complex (MHC) and is stil one
of the major determnants of allograft success.
The fourth key discovery was made by Thomas Gibson and Peter Medawar
during their cumulative experience using skin allografts to treat burned aviators from
World War n. In these studies they noted that autografts typically survived. In contrast
allografts universally failed within 15 days, and a repeat of a failed allograft typically
rejected even faster (8 days) (17). Furthermore, they also showed that rejected grafts were
invaded by white blood cells, confirmng the immunological nature of graft rejection
(17). For helping to jumpstar the field of transplantation biology, the Nobel Prize was
awarded to Alexis Carel in 1912 , to Karl Landsteiner in 1930 and to Sir Peter Medewar
in 1960. Together, these were the pioneers of modem day transplantation.
C. The dawn of immunosu ression
The pioneering work of Thomas Gibson and Peter Medawar showing that
allograft rejection was the result of an active immune response led to the use of
immunosuppressive drugs in transplantation, in the hope that this immune response could
be suppressed. The first form of immunosuppression was whole body irradiation (18 19).
Although this form of immunosuppression led to allograft acceptance in a few cases,
including the first successful kidney transplant performed by Murray and Merrll in 1954
(20), the majority of times it was unsuccessful (21). Furthermore, this non-specific form
of immunosuppression proved to be highly toxic and was associated with a very high rate
of mortality due to overwhelmng infection (21).
The first drug to replace whole body irradiation was 6-mercaptopurine (6-MP).
This drg, discovered in 1959 by Schwarz and Dameshek, trpled the survival time of
skin allografts in rabbits (22). The British surgeon Sir Roy CaIne popularzed a similar
form of immunosuppression, azathioprine (AZA), a precursor of 6-MP. Using AZA
Calne suppressed renal transplant rejection in dogs (23). Although 6-MP and AZA
substantially reduced the risk of rejection, they both were associated with toxic side
effects including predisposition to infection and anemia, as well as bone marow
suppression (1).
The key breakthrough in immunosuppression came in 1969 when Jean Borel
discovered a fungus (Beauveria nivea) in soil samples from Wisconsin and the Hardanger
Vidda fjord in Norway. Several years later he discovered the immunosuppressive
properties of the metabolite produced by this fungus, cyclosporine (CsA). More
importantly, he discovered that CsA did not produce the severe side effects that were
associated with 6-MP or AZA (24). In 1978, CsA was tested for the first time on humans.
In a small cohort of 7 kidney transplant recipients, 5 patients successfully accepted their
organ (25).
CsA was a major improvement over all other immunosuppressive drugs for
several reasons. Previous immunosuppressants, such as 6-MP and AZA, suppress all
immune cells, resulting in the inability of the immune system to mount a response to
virtually any type of infection. CsA, on the other hand, selectively suppresses only T
cells, leaving all other immune cells intact and capable of responding to infection.
Second, unlike 6-MP and AZA, CsA is not associated with severe bone marow
suppression and anemia. The use of CsA dramatically improved I-year survival rates of
transplanted organs such as kidney, hear, liver and pancreas from 50-60% to over 80%
(26,27). Unfortunately, it was eventually discovered that CsA had its own concernng
side effects , including renal dysfunction, tremor and hypertension (28).
Since the discovery of CsA, many other immunosuppressive drgs have been
identified. This long list includes a monoclonal antibody directed against CD3 (OKT3)
(29), tacrolimus (FK-506) (30), rapamycin, mycophenolate mofetil and leflunomide
(27 31). The use of CsA and newer immunosuppressive drugs has greatly improved graft
survival, but major side effects stil exist. Current immunosuppressive agents specifically
target only T cells, instead of all immune cells, but they stil induce a generalized
immunosuppression that predisposes patients to infections and malignancies. The
statistics associated with long-term use of immunosuppression is alarng: 10-45% of
these patients develop a neoplasm after 10 years and 40-75% after 20 years (32 33). A
second major concern of current immunosuppressive therapies is the lack of long-term
organ survival due to the onset of chronic rejection. Whereas almost all kidney
transplants are fully functional after I year, only 20% remain functional 10 years after
transplantation (34). Finally, immunosuppression is unable to prevent the recurrence of
tissue-specific disease or autoimmunity that might damage the newly transplanted organ
(35).
D. A future without immunosuP\Jression
Currently, researchers are seeking alternatives to immunosuppression that wil
prevent both short-term and long-term graft rejection while remaining as safe as possible
for the recipient. Many laboratories have focused on the induction of transplantation
tolerance as a way to overcome the deficiencies associated with generalized
immunosuppression. Transplantation tolerance is a state of non-responsiveness to one
specific donor while all other immune responses remain intact. As the discovery of CsA
reduced the target of immunosuppression from all immune cells to just T cells,
transplantation tolerance would reduce the target of therapy from all T cells to just those
T cells that recognize and destroy the allograft. In theory, this would leave all other T
cells intact, considerably reducing the risks of infection and neoplasia for transplant
recipients.
2. Transplantation Immunology
A. Imune res onse to allo afts
In order to prevent the rejection of an allograft without globally blocking the
immune response, one must first understand the nature of the immune system s response
to an allograft. Transplantation of an organ from one individual to another invokes many
different facets of the immune response, and therefore requires knowledge of the varous
stages of the response, as well as of the different cell types that are involved.
The first host response to a newly transplanted allograft involves inflamation
resulting from the transplantation process and the trauma associated with it. Removal of
the allograft from the donor and transplantation into the host causes the induction of
cytokines such as IL- l and IL-6 and increased expression of adhesion molecules on the
graft's endothelium (36, 37). These two events combine to cause an early infitration 
the transplant by inflamatory cells, including macrophages (38). These early events
occur in both syngeneic transplants (between identical members of the same species), as
well as in allogeneic transplants (between different members of the same species), and
typically do not result in graft rejection (39).
The next stage of the immune response to an allograft is the presentation of
foreign antigen to host T cells. The single most important alloantigen presented to T cells
is the major histocompatibility complex (MHC) (40). The presentation of this alloantigen
can occur in one of two distinct ways. Donor antigen presenting cells (APCs), such as
dendrtic cells (DCs) can present donor MHC directly to host T cells in what is called
direct antigen presentation. Conversely, allogeneic MHC antigens can be processed by
host APCs and presented in association with host-MHC in what is called indirect antigen
presentation.
B. Mechanisms of aft re ection
Following the presentation of foreign antigen, T cells become activated
proliferate and initiate the rejection of the transplanted allograft through varous humoral
and cellular effector mechanisms. B cells can produce antibodies to the alloantigen and
initiate antibody-dependent cell-mediated cytotoxicity (ADCC) (41) or they can bind
complement and initiate complement-mediated lysis of the targeted graft (42). Natural
killer (NK) cells can damage the allograft by the release of perforin or granzymes (43).
Finally, activated T cells can cause graft rejection through a varety of effector
mechanisms. T cells can activate macrophages to initiate delayed-type hypersensitivity
(DTH) reactions or damage allografts through the release of reactive nitrogen , oxygen
intermediates, and TNF-a (44). Alternatively, T cells can become cytotoxic T
lymphocytes (CTL) and destroy targeted cells through the release of either TNF-
a, perforin or granzyme, or via the activation of the Fas-FasL pathway (45).
Although several different effector mechanisms are involved in allograft rejection
it is believed that T cells play the most important role. This is supported by the discovery
that both mice and rats that lack T cells are unable to reject allografts (46 47). It is for this
reason that many laboratories are focusing on understanding T cell activation in hopes of
being able to prevent allograft rejection as specifically as possible.
3. T Cell Activation
A. T cell activation: the two-si nal h othesis
Based on a two-signal model of B cell activation proposed by Bretscher and Cohn
(48), Lafferty et al. proposed a similar two-signal model for the activation of T cells.
According to his proposal, T cells require the interaction of their T cell receptor (TCR)
with a specific antigen-MHC complex presented on antigen presenting cells (Signal I)
along with a different signal (Signal 2) provided by APCs (49). Supporting this model, it
was found that T cells stimulated with Signal 1 alone did not become activated. Instead
they became anergic, characterized by a state of unresponsiveness (50).
Currently, it is believed that Signal 2 (co stimulation) is given by the interactions
of CD154 with CD40 and by the interaction of CD80 and/or CD86 with CD28. Many
additional molecules are able to modulate T cell activation and provide costimulation, but
the costimulatory signals provided by these molecules appear to be less potent than those
provided by the interaction of CD40 with CD154 and CD80/86 with CD28. These
additional accessory molecules include a member of the integrn famly (LFA- l (51)), a
member of the CD2 subfamily (CDw150 also called SLAM (52)), and members of the
tumor necrosis factor receptor (TNF) famly (CD137 (53), CD134 (54), and CD27
(55)). Although these molecules do playa role in T cell activation they are considered
minor players compared to the CD40-CD154 and CD80/CD86-CD28 pathways.
B. Costimulation: Role of CD40-CD154 interactions
CD40 is a type- l integral membrane protein and a member of the TNF
superfamly (56). The protein has a molecular weight of 43-50 kDa, and is expressed on
many cell types including T and B cells , basophils , eosinophils, monocytes/macrophages
dendrtic cells, epithelial and endothelial cells, smooth muscle cells, keratinocytes and
fibroblasts (57). CD40 is constitutively expressed on all cell types , but its expression can
be modified by varous cytokines in both a positive and negative fashion. IL- , IL- , IL-
, TNF-a and granulocyte/macrophage colony stimulating factor (GM-CSF) all enhance
the expression of CD40 (58-60), while TGF- j3 inhibits CD40 expression (61). The up-
regulated expression of CD40 takes 6- 12 hours to occur, peaks at 24 hours and is
maintained on the cell surface for up to 72 hours (57).
CD154, the ligand for CD40, is a type-2 transmembrane protein with a molecular
weight of -39 kDa and is a member of the TNF gene superfamily (56). CD154 is
expressed on a number of different cell types, many of which express both the ligand and
its receptor. The expression of CDl54 has been found on activated B and T cells
basophils , eosinophils , monocytes/macrophages, NK cells , platelets, mast cells, dendrtic
cells , endothelial cells , epithelial cells , and smooth muscle cells (57). CD154 expression
as opposed to its receptor, is non-constitutive. Expression can be induced by varous
mitogens (ionomycin, the combination of phytohemagglutinin along with concanavalin
, and PMA (62)), by several different proinflammatory cytokines (IL- , TNF-a and IL-
4) (63-65), or by CD40 ligation (66). The expression of CD154 on the cell surface is
typically transient. In T cells, CD154 is expressed 5 minutes after activation (67), peaks
at 6 hours and steadily declines to undetectable levels by 12-24 hours following
activation (68).
The CD40-CD154 pathway was first observed to be critical for the development
of humoral immunity to T cell-dependent antigen responses (69 70). This pathway has
now been shown to be critical for the induction of many functions in both humoral and
cellular immunity. Blocking the CD40-CD154 pathway prevents primary and secondary
immune responses to T cell dependent antigens, the maturation of B cell memory,
germnal center formation and immunoglobulin class switching (70 71). The CD40-
CDl54 pathway is also critical for the release of many pro-inflamatory cytokines (IL-
IL- , IL- , IL- , IL- , IL- , TNF- a and TGF-I3), chemokines (IL- , MIP- l a, MIP-
113, RAES and MCF- l) and the upregulation of adhesion molecules (LFA-a, ICAM-
VCAM- , E-Selectin and VLA-4) (57).
C. Costimulation: Role of CD80/86-CD28/CTLA4 interactions
The second major set of molecules that provide costimulation for T cells are the
ligands CD80 (B7- 1) and CD86 (B7-2) and their receptors CD28 and CTLA- (72).
CD80 and CD86 are members of the immunoglobulin gene superfamily. CD80/86
expression can be up-regulated on monocytes, dendritic cells , langerhans cells, B cells
and T cells after activation by mitogens, MHC class n ligation, cell surface Ig cross-
linkng, the ligation of CD40 or a varety of cytokines (73 74). In addition CD86
expression is also constitutive on resting monocytes and dendritic cells (74).
CD28 , an Ig superfamly glycoprotein, is constitutively expressed on both resting
and activated T cells, and its expression does not fluctuate significantly after T cell
activation (75). CD28 ligation induces several changes in the T cell that stimulate both
the magnitude and duration of the T cell response. These changes include upregulated
expression of the anti-apoptotic gene BCL and increased production of cytokines, such
as IL-2 (76). However, CD28 signaling is not necessary for all T cell responses, as CD28
knockout mice can clear an LCMV infection and reject skin allografts (77-79).
A second receptor for the ligands CD80 and CD86 is CTLA-4 (72). CTLA-4 is a
glycoprotein in the CD28 family, but has several different features than CD28. CTLA-
unlike CD28 , is not expressed constitutively but rather is upregulated after CD28 ligation
(80). Once expressed, CTLA-4 has a much higher affinity and avidity for its ligands
CD80 and CD86 than CD28 (81). Finally, whereas CD28 ligation gives a positive signal
for T cell activation, CTLA-4 ligation appears to give a negative signal to the T cell and
inhibits the synthesis of IL-2 (82). The role of CTLA-4 as a negative regulator of T cell
activation is further supported by the finding that CTLA-4 deficient mice develop a fatal
lymphoproliferative disorder (82).
CD80 and CD86 are the only two ligands known to interact with the two receptors
CD28 and CTLA- , and vice versa. Recently however, other novel members of both the
B7 and CD28 famlies have been discovered. These include the receptors ICOS and PD-
and their respective ligands B7H and B7Hl (83,84). Similar to CD28 and CTLA- , ICOS
has been shown to give a positive signal for T cell activation, while PD- l inhibits T cell
activation (72). Although these new ligands and receptors appear to be involved in T cell
activation and inhibition, their exact roles are stil being elucidated.
D. Redefinin T cell activation: a three ste
p p
rocess
Based on our current understanding of T cell activation, we now believe that there
are 3 required steps for complete T cell activation (35). Initially, the TCR interacts with
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its cognate antigen-MHC complex on the APC (Step 1). This interaction induces the
upregulation of CD154 on the T cell surface (68). The newly expressed CD154 then
interacts with its constitutively expressed receptor on the APC, CD40. The completion of
the CD40-CD154 interaction (Step 2) induces B7- 1(CD80) and B7-2 (CD86) expression
on the APC (85). CD80 and CD86 bind to the constitutively expressed CD28 receptor on
the T cell (Step 3) allowing the T cell to become fully activated. Forty-eight to seventy-
two hours after T cell activation, CTLA-4 becomes expressed on the T cell surface
which may represent a means of down regulating T cell activation (86). A schematic of
these 3 interactions necessary for complete T cell activation is shown in Figure I.

Legend to Figure 1: This figure schematically depicts the 3 steps of T cell
activation. Specifically, it shows the activation of an alloreactive T cell by an APe. The
first step of activation is the interaction of the TCR with the antigenlC complex on
the APe. This interaction induces the expression of CD154 on the surface of theT cell.
Newly expressed CDl54 interacts with constitutively expressed CD40 found on the APC.
The interaction of CD40 with CD154 (Step 2) induces the upregulation of B7- 1 (CD80)
and B7-2 (CD86) expression on the APC. Finally, CD80 and CD86 bind to the
constitutively expressed CD28 molecules on the T cell (Step 3) allowing the alloreactive
T cell to become fully activated.
4. Immunological Tolerance
A. Definition of tolerance
order the deficiencies associated with generalizedovercome
immunosuppression many laboratories have focused on the induction of transplantation
tolerance. Transplantation tolerance is a state of non-responsiveness to one specific donor
while all other immune responses remain intact. In theory, transplantation tolerance is the
least toxic method for successful transplantation, as all other T cells wil remain
unaffected, thereby reducing the risks of infection and neoplasia associated with
immunosuppression.
Although tolerance is defined as a state of non-responsiveness to antigen in the
absence of immunosuppression, it can be further broken down into two distinct
definitions, functional tolerance and immunological tolerance. Functional tolerance is
based solely on graft outcome, and is defined as a graft that survives without the need for
immunosuppression. In contrast, immunological tolerance is based solely on the immune
response, and is defined as the lack of an immune response to a graft in the absence of
immunosuppression (35). The distinction between these two definitions of tolerance was
created because some forms of tolerance endure even in the presence of immune
reactivity against the graft (87). Furthermore, the maintenance of tolerance is sometimes
associated with graft infiltrates (88). In this thesis we use the functional definition of
tolerance, as we focus on graft survival.
B. Discovery of central and peripheral tolerance
Owen first described tolerance in 1945 , performng skin allografts on Freemarin
cattle twins who share a placenta during gestation. He discovered that allografts between
freemarin cattle twins survived without the use of immunosuppression, whereas skin
allografts between non-twins failed (89). He hypothesized that tolerance was the result of
alloantigen exposure to the immune system during early development (89).
These observations were extended by the work of Billngham and Burnet.
Bilingham observed that a state of tolerance could be experimentally induced when
allogeneic cells were injected into neonatal recipients (90). Similarly, Burnet observed
that neonatal mice infected with lymphocytic choriomeningitis virus (LCMV) became
persistently infected with the virus (91). These observations led Burnet to develop a
theory of clonal selection to describe how the immune system distinguishes self from
non-self. His theory proposed that self-reactive cells were deleted in central lymphoid
organs , leaving all non-self reactive cells intact (91). It is now known that the deletion of
self-reactive T cells, called negative selection, takes place in the thymus. A second
process in the thymus, called positive selection, selects for T cells that recognize foreign
antigen in the context of self-MHC.
Burnet s theory of clonal deletion is accurate, but does not explain the complete
story of tolerance. Some antigens may never be expressed in the thymus, and therefore
negative selection to these antigens would never occur. Furthermore, self-reactive cells
have been detected in peripheral tissues, suggesting that some self-reactive cells can
avoid the process of negative selection (92). In order for these self-reactive cells to be
controlled, the immune system has developed a second form of tolerance that takes place
in the periphery, called peripheral tolerance.
5. Peripheral Tolerance
A. Mechanisms of induction and maintenance
Four major mechanisms have been proposed to maintain peripheral tolerance:
anergy, ignorance, suppression and deletion. Anergy results from T cells receiving Signal
1 (TCR-MHC/Ag) in the absence of Signal 2 (costimulation) (50). Anergy is
characterized by a state of unresponsiveness and is associated with decreased IL-
production (93) and the down-regulation of TCR surface expression (94 95). This
unresponsive state can usually be broken by the addition of exogenous IL-2 (96).
A second mechanism proposed to maintain peripheral tolerance is ignorance (97).
Ignorance is characterized by a state of unresponsiveness , but, unlike anergy, these T
cells are stil capable of proliferation when incubated with their respective antigens 
vivo. It has been suggested that ignorance occurs because certain T cells are unable to
contact their specific antigen due to an inability to migrate into the specific area where it
is being presented (98).
A third form of peripheral tolerance, suppression, has been used to explain the
presence of alloreactive T cells (99) and cellular infiltrates (100) that are sometimes
found in healthy grafts. Further support for suppression comes from the observation that
T cells from a tolerized animal can induce a similar state of unresponsiveness when
adoptively transferred into untreated recipients , also known as infectious tolerance (101).
A fourth form of maintaining peripheral tolerance is deletion. Support for deletion
comes from the observation that antigen-specific T cells are deleted following exposure
to high doses of alloantigen (102), viral antigens (103) or superantigens (104). One
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suggested mechanism accounting for deletion is the production of cytokines, as IL-4 and
IL- IO were implicated in the deletion of allo-reactive cells in one study (105). A second
mechanism that may be involved is the Fas-FasL pathway. Using transgenic mice
specific for pigeon cytochrome C, Singer and Abbas observed that antigen-induced
peripheral deletion occurred in wild-type mice but not in Faslpr/ Faslpr mice that expressed
a defective Fas gene (106).
B. Methods of eri heral tolerance induction in vivo
To induce peripheral transplantation tolerance, many experimental protocols
focus on the interference of T cell activation. These protocols typically involve blocking
the interactions of molecules involved in Signal 1 (107) or Signal 2. Strategies that
interfere with Signal 1 , the interaction of TCR with the MHC-peptide complex , include a
mAb specific for CD3 (OKT3) (108), or antibodies that mask MHC class lor II (109).
Other strategies have focused on blocking costimulation (Signal 2). These strategies
focus on blocking the varous costimulatory interactions, including CD80/CD86 with
CD28 and CTLA- , CD40 with CD154 , and LFA- l with ICAM- l (110- 114).
C. Peri heral tolerance induced b DST and anti-CDl54 mAb
Our laboratory has focused on the interaction of CD40 with CDl54 to induce
peripheral transplantation tolerance. Our approach, as diagramed in Figure 2, uses a
two-element protocol involving the combination of a single injection of allogeneic
splenocytes as the donor-specific transfusion (DST) and a short course of anti-CDl54
mAb. We originally hypothesized that this protocol led to the exposure of alloantigen to
'" "
Figure 2. Induction of Transplantation Tolerance:
A two-element protocol
Anti-CD154 mAb (0.5 mg/dose , i.
Day - Day - Day 0 Day +3
DST:
BALB/c Splenocytes
(i. v.
BALB/c Skin
Allograft
Legend to Figure 2: This figure depicts our laboratory s two-element protocol to
induce donor-specific peripheral tolerance. C57BL/6 recipient mice receive a singe Lv.
injection of BALB/c donor splenocytes on day -7 (7 days prior to skin transplantation)
along with four (0.25 mg) injections of anti-CDl54 mAb given on days -
, -
, 0 and +3
relative to receiving a BALB/c skin graft on day 
host T cells under conditions where CDl54 could not interact with its receptor, CD40.
The presence of Signal 1 in the absence of Signal 2 would render allo-specific T cells
specific for cells and tissues that express the donor alloantigen anergic , while all other T
cells would remain unaffected (115).
Initially, our laboratory s protocol was tested using pancreatic islet allografts
(116). The combinatorial treatment of DST and anti-CDl54 mAb induced permanent islet
allograft survival in 96% of chemically induced diabetic mice (116). As a more rigorous
test of transplantation tolerance, we next tested whether our two-element protocol could
induce transplantation tolerance to skin allografts (115), as skin allografts represent a
robust test of tolerance induction. The combination of DST and anti-CDl54 mAb
prolonged the survival of murine skin allografts to a median survival time of -50 days
with graft survival reaching 1 00 days in 20% of treated mice (115).
The combination of a short treatment period along with a simple and minimal
conditioning regimen led us to believe that this protocol could be translatable to the
clinic. However, although our two-element protocol extended the survival of skin
allografts , rejection stil occurred roughly 50 days after treatment (115). In contrast, when
thymectomized mice were used as recipients, permanent skin allograft survival was
observed (117). This suggested that DST and anti-CDl54 mAb might induce
transplantation tolerance through the deletion of pre-existing peripheral alloreactive T
cells. These results also suggested that newly exported alloreactive T cells from the
thymus might be the cause of delayed skin allograft rejection in tolerized mice.
In order to test these hypotheses, we set up a Jenkns-like model system
(118, 119). This assay involves the adoptive transfer of a small population of transgenic T
cells into syngeneic non-transgenic hosts. This transfusion permts low level engraftment
of the tracer transgenic population in a wild-type host unaltered by transgene expression.
Our modified version of the Jenkns assay involved the injection of a small tracer
population of transgenic T cells (KB5 CD8+ T cells specific for H2 ) into syngeneic wild-
type hosts (CBA/JCr). The engraftment of KB5+CD8+ T cells , as well as their fate, was
monitored with the use of a c1onotypic mAb (DES) that recognizes specifically the
transgenic CD8+ T cells. Following successful engraftment, mice were treated with our
two-element protocol of DST (C57BL/6 (H2 ) splenocytes) and anti-CDl54 mAb and
subsequently given a donor-specific skin allograft (C57BL/6). Confirmng our previous
hypotheses , we observed the deletion of KB5+CD8+ T cells 2-3 days following treatment
with DST and anti-CDl54 mAb (120).
In total, these results suggest that treatment of mice with DST and anti-CDl54
mAb induce peripheral transplantation tolerance through the deletion of circulating
alloreactive CD8+ T cells. Unfortunately, the results of our thymectomy study point out a
major problem with inducing donor-specific peripheral tolerance through deletion.
Namely, deleted cells can eventually be replaced with newly exported alloreactive T
cells. Likewise, the induction of peripheral donor-specific tolerance through anergy,
suppression or ignorance may also fail to permanently tolerize recipients due to cross-
reactivity of T cells or virally induced proinflammatory stimuli (121). Because of these
concerns , our laboratory searched for other means of inducing donor-specific tolerance
that would lead to permanent tolerance to all allografts in euthymic recipients. One
attractive possibilty was the induction of donor-specific central tolerance, and in
paricular, the creation of a hematopoietic chimera through successful bone marrow
transplantation.
6. Central Tolerance
The injection of antigens directly into the thymus (122) and the creation of
hematopoietic chimeras (123) are two of the most common means of inducing central
transplantation tolerance. The focus of this thesis work is the induction of central
tolerance by bone marow transplantation. Therefore, the focus of this section wil be on
the induction of central tolerance by bone marow transplantation.
A. Histor of bone marow trans lantation
The field of bone marow transplantation can be traced as far back as 1951. In a
landmark experiment, Lorenz et al. observed that mice given a normally lethal dose of
irradiation survived if given bone marow cell infusions immediately after irradiation
(124). Four years later, Main and Prehn observed that successful bone marow
transplantation resulted in donor-specific tolerance. In their experiments, skin grafts
permanently survived in lethally irradiated mice given bone marow transplants when
skin grafts were from the same donor as the bone marow (125).
Based on these early studies in animals , E. Donnall Thomas and colleagues
performed the first successful bone marow transplant in humans in 1959 (126). His
patients were two pairs of identical twins. In each pair, one of the twins suffered from
acute lymphocytic leukemia. After treatment with irradiation and a bone marow graft
from the genetically identical healthy twin, both patients showed significant restoration in
bone marow function. Unfortunately, both patients had a recurrence in their leukemia
and died within a few months (126).
The experiments of Thomas and colleagues led to great optimism for the use of
bone marow transplantation to successfully treat leukemia. Unfortunately, the vast
majority of bone marow transplants were unsuccessful unless bone marow from 
identical twin donor was used (126). During the 1950s and early 1960s over 200
allogeneic bone marow transplants were performed in humans , without a single success
(127).
Although the human equivalent of the mouse MHC (HLA-Human leukocyte
antigen) was discovered in 1958 (128 129), it wasn t until the late 1960s before the
importance of the HLA system in bone marow transplantation was fully understood. In a
seminal experiment performed with dogs, bone marow transplants between DLA-
matched (dog leukocyte antigen) littermates were successful, while DLA-unmatched
transplants failed (130). Based on these studies, the first human HLA-compatible
allogeneic bone marow transplants were successfully performed in 1968 and 1969 on
patients with various immune deficiency diseases (131- 133).
Although some allogeneic bone marow transplants were successful, the majority
of bone marow transplants failed. The one exception to this rule was
immunocompromised patients (134). As was tre with organ transplantation, a greater
understanding of the immune response to bone marow transplantation was necessary
before successful allogeneic bone marow transplantation would be feasible.
B. Bone marow trans lantation: induction and maintenance
The use of bone marow transplantation is the most popular means to induce
central transplantation tolerance. The varous stages of bone marow transplantation that
occur in order to achieve tolerance are shown in Figure 3. When donor hematopoietic
stem cells are injected into a recipient, they are capable of engrafting into the bone
marow and co-existing with host stem cells (135). If engraftment occurs , both donor and
host stem cells mature and produce cells of all hematopoietic lineages. Additionally,
certain bone marow-derived cells called thymic dendrtic cells travel to the thymus and
engraft. These cells are particularly good mediators of intrathymic clonal deletion (136).
As bone marow-derived thymocytes are produced they travel to the thymus to mature
and undergo positive and negative selection. Positive selection keeps thymocytes that
recognize foreign antigens in the context of self-MHC alive , whereas negative selection
deletes T cells that recognize self-antigens. The combination of these two processes
ensure that only T cells that express self-MHC and recognize foreign antigens wil
survive and be exported into the periphery. The majority of cells (::95%) are not selected
for and die in the thymus via apoptosis (121). After successful bone marow engraftment
both donor and host thymic dendrtic cells are present in the thymus, and as a result, both
donor and host antigens are presented as self-antigens to maturing T cells. As a result of
negative selection, both host-reactive and donor-reactive T cells are deleted in the
thymus , ensuring a permanent state of donor-specific tolerance.
In order to achieve this state of donor-specific tolerance, successful bone marow
transplantation requires that two major issues be resolved. These issues include creating
space" to allow donor bone marow to engraft and expand, and preventing the initial
rejection of donor bone marow.
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Legend to Figure 3: This figue depicts the induction of central transplantation
tolerance by bone marow transplantation. After injection, hematopoietic cells engraft
into the bone marrow and coexist with host hematopoietic cells. Donor hematopoietic
cells mature in the marow and produce erythrocytes, B cells , granulocytes , and other
hematopoietic derived cells. Imature donor thymocytes travel from the marow to the
thymus and engraft, where they help mediate negative selection of donor-reactive T cells
and ensure permanent central transplantation tolerance is maintained. This schematic is a
modified version of a figure originally published by M. Sykes (Transplantation.
68(4):459-467 , 1999)
In order for donor bone marow to engraft, it is believed that "space" needs to be
created in the bone marow comparment. This concept is supported by experiments in
which 1. 0 Gy of irradiation was necessary to produce long-term syngeneic bone
marow engraftment in C57BL/6 mice (137). Others have been able to obtain long-term
bone marow engraftment with high doses of donor bone marow without the use of
irradiation (138-142). As opposed to the idea that "space" needs to be created, these
results suggest that host and donor bone marow may compete for space to expand. This
concept is supported by studies of allogeneic bone marow transplantation in autoimmune
mice, where the engraftment of donor allogeneic bone marow was able to "out-compete
host autoimmune stem cells (143).
The second concern in bone marow transplantation is preventing host T cells
from rejecting donor bone marow. In order to suppress these donor-reactive T cells , the
use of lethal whole body irradiation was originally used. Lethal whole body irradiation
would be desirable for treating hematological disease and leukemias, as it would also
eliminate the tumor. In all other cases, however, the severe side effects and possibility of
lethality due to unsuccessful engraftment make lethal whole body irradiation clinically
unfeasible. In the attempt to create a less toxic and therefore more clinically relevant
protocol for bone marow transplantation, many laboratories are developing sub-lethal or
non-myeloablative. approaches to induce bone marow engraftment. The varous
protocols that have been devisecl to induce allogeneic bone marow engraftment under
sublethal or non-myeloablative conditions , in both humans and mice, are discussed next.
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e. Inducing central transplantation tolerance in humans
Currently, over 18,000 bone marow transplants are performed in the United
States each year and 40,000 worldwide (144). Bone marow transplantation is used to
treat aplastic anemia, immunodeficiency syndromes, congenital disorders of metabolism
and neoplastic diseases (144). Typical conditioning regimens for human bone marow
transplantation involve the use of total body irradiation (TBI) in either single or multiple
doses. Total body irradiation is used to prevent graft rejection, to create "space" in the
bone marow comparment, and to treat the underlying malignancy (145). The alkylating
agent busulfan is also used as a substitute for TBI (146). Along with TBI or busulfan, a
myelosuppressive and/or immunosuppressive drug, such as cyclophosphamide, is
typically added to the conditioning regimen to reduce the incidence of disease relapse
(147). The combination of TBI or busulfan along with cyclophosphamide has decreased
the incidence of graft rejection to .:1 % (146). In one published study following patients
who underwent bone marow transplantation for chronic myeloid leukemia, lO-year
survival rates were 63-65% using either of these two conditioning regimens (148).
Current protocols have effectively decreased the occurrence of graft rejection and
disease relapse in bone marow transplant recipients. Unfortunately, these conditioning
regimens are associated with many debiltating side effects; which include veno-
occlusive disease, GVHD, and a high incidence of bacterial, fungal, and viral infections.
Veno-occlusive disease (VOD) is the third leading source of transplant-related
mortality in allogeneic bone marow transplant recipients (149). The disease results from
loose connective tissue blocking intrahepatic veins in the liver (150). VOD manifests
within 20 days of transplantation (151) and causes unexplained weight gain, jaundice
and pain in the upper half of the body (152). VOD affects as many as 54% of bone
marow transplant recipients (153), with a reported mortality rate ranging as low as 3%
and as high as 67% (150). Both chemotherapy and radiotherapy have been associated
with VOD, especially the use of busulfan (154).
The second leading cause of death for bone marow transplant recipients is
GVHD (149). GVH results from passenger T cells in donor bone marow recognizing
host antigens as foreign and initiating an immune response against them (152). By
definition GVH is broken down into either acute (occurs within 100 days of
transplantation) or chronic forms (occurs after 100 days of transplantation).
Acute GVHD involves injury to the epithelial tissues of the liver, gastrointestinal
tract and skin (155). This disease affects more than 30% of bone marow transplant
recipients, with a mortality rate of -20% (152 156 157). Incidence of acute GVHD is
associated with HLA disparty, and can reach as high as SO% in those patients who
receive bone marow from an unrelated donor (15S).
Chronic GVHD manifests clinically as an autoimmune-like disease, typically
affecting the skin, eyes , liver, intestines and esophagus (155). Incidence rates for chronic
GVHD are greater than 30% , with a rate as high as 60% for patients who receive bone
marow from unrelated donors (159). Mortality rates for chronic GVHD, as in acute
GVH, approach 20% (156). Chronic GVHD is more common in older patients, patients
who have aleady experienced acute GVHD , and in recipients of unrelated bone marow
(160).
The two most common treatments for preventing GVHD are the use of T cell
depleted donor bone marow and the use of immunosuppressive drgs such as CsA (152).
T cell depletion of donor bone marow correlates with much lower incidences of GVHD
than cyclosporine (10% VS. 30-40% with cyclosporine) (145). However, it is associated
with higher rates of graft failure (109) and increased rates of disease relapse (161). The
existence of a facilitating CD8+ T cell for stem cell engraftment in mice has been
reported (162) and may be the cause of decreased engraftment using T cell depleted bone
marow.
The number one cause of mortality and morbidity in allogeneic bone marow
transplant recipients is infection (149). Infection can result from an infected organ or
blood product, re-emergence of a latent viral infection, or as a result of radiation-induced
damage to the mucosa or the prolonged neutropenia that follows radiotherapy (144).
Clinicians use three separate risk periods for the infection of bone marow transplant
recipients: the pre-engraftment period, the early post-engraftment period and the late
post-engraftment period (163).
The pre-engraftment period covers the first month after bone marow
transplantation. This time period is associated with severe neutropenia resulting from the
use of irradiation or myeloablative drgs (144). Infections during this period include
bacterial (Gram-negative and Gram-positive bacteria), fungal (Candida and Aspergillus),
and viral (herpes simplex virus (HSV)) (164-166). Bacterial and fungal infections
typically lead to neutropenic fever, although if untreated, infection can lead to organ
failure and even death (144).
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The early engraftment period covers the time period between 30 and 100 days
after bone marow transplantation. During this time period neutrophil numbers are
recovering, but T and B cell functions are stil suppressed and remain so for up to 18
months (163). Bacterial and viral infections are less frequent, but stil occur in patients
who receive unrelated bone marow or are suffering from GVHD (167). Common viral
infections during this period include cytomegalovirus (CMV), HSV, adenovirus and BK
virus.
The third risk period for bone marow transplant recipients is the late post-
engraftment period. This period begins at 100 days after transplantation and termnates
18-36 months later, as patients discontinue the use of immunosuppressive drgs (163).
Even at this late time point, cellular and humoral immunity remains suppressed
especially for those patients suffering from GVHD or recipients of unrelated donor bone
marow (144). As a result, patients are prone to viral infections such as varcella zoster
virus (VZV), CMV and Epstein-Bar virus (EBV) (163).
Together, the incidence of VOD, GVHD and infection (fungal, bacterial and viral)
poses a serious risk of morbidity and mortality to bone marow transplant recipients. As a
result, a new wave of bone marow transplant conditioning regimens have recently been
initiated (168-172). These less toxic regimens, dubbed "mini-transplants , focus on
sublethal or non-myeloablative conditioning (168). Mini-transplants hope to minimize
post-transplant neutropenia, thereby lowering the high incidence of VOD and infection
associated with bone marow transplantation. Of equal importance, lowering the toxicity
required for bone marow transplantation would allow this therapy to be a viable option
for elderly patients, as well as patients with nonmalignant diseases (173). Another
exciting application of sublethal mini-transplants is the possibility of simultaneous bone
marow and organ transplantation. In theory, donor-specific tolerance induced by bone
marow transplantation would eliminate the need for lifelong immunosuppression in solid
organ transplantation. In one preliminary study the simultaneous transplantation of bone
marow and kidney was able to successfully cure a patient with multiple myeloma (174).
Mini-transplants have the potential to revolutionize the field of bone marow
transplantation (173). However, the abilty of these new protocols to reduce the rates of
infection and GVHD are stil relatively unkown, as are the affects on long term survival
and disease relapse. In one study looking at 12 patients who had undergone non-
myeloablative peripheral stem cell transplantation, 17% of patients became infected with
bacteria and 42% with CMV, suggesting that infection stil poses a significant problem
at least with this paricular regimen (175).
Before going in depth on our paricular conditioning regimen, sublethal protocols
for bone marow transplantation in mice wil be reviewed with an emphasis on those that
utilze costimulation blockade.
D. Inducin central trans lantation tolerance in mice: the future
For over 10 years, researchers have successfully transplanted allogeneic bone
marow in mice without the need for lethal whole body irradiation (176). These
protocols, for the most par, are based on combinatorial regimens that include low levels
of myeloablative drugs or sublethal irradiation in order to create "space" in the recipient
marow. Additionally, these regimens include either T cell depleting mAbs, thymc
irradiation (TI), antibodies that block costimulation (anti-CD80, anti-CD86, anti-CDl54
and CTLA4- Ig), CsA, or a combination of these varous reagents to prevent allograft
rejection (4 177- 185).
One of the original sublethal conditioning regimens consisted of depleting doses
of anti-CD4 and anti-CD8 mAbs , along with 3 Gy of whole body irradiation (WI) and 
Gy of thymc irradiation (TI) (176). Further modification of this protocol showed that 
could be replaced by either additional injections of anti-CD4 and anti-CD8 mAbs (177),
or by a single injection of CTLA4-Ig or anti-CDl54 mAb (186). The use of anti-CDl54
mAb led to a higher level and rate of chimerism than mice treated with CTLA4-Ig.
Combined treatment of these reagents showed no improvement over treatment with anti-
CD154 mAb alone.
All of these vlliations consistently induced mixed hematopoietic chimerism, as
treated mice contained hematopoietic cells derived from both donor and host stem cells.
Furthermore, donor-specific tolerance was established. Chimeric mice permanently
accepted donor-specific skin grafts and rejected third pary grafts. Although these
sublethal regimens consistently led to hematopoietic chimerism and donor-specific
tolerance, the use of anti-CD4 and anti-CD8 mAbs caused prolonged T cell depletion in
recipient mice.
In contrast to the experiments above, some researchers have demonstrated that the
combination of CTLA4-Ig and anti-CD154 mAb is better than the use of either reagent
alone. Salam et al. have observed that either CTLA4-Ig or anti-CDl54 mAb alone was
insufficient for the engraftment of CBA/J bone marow into BALB/c mice treated with 3
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Gy (185). In contrast, the combination of both reagents allowed successful bone marrow
engraftment at 3 Gy (185). Unfortunately, very low numbers of mice were used in this
study (groups of 5-6 mice), and only 40% of mice became chimeric. Increasing the dose
of CTLA4-Ig and anti-CDl54 mAb, however, could increase this rate to 67%.
Taylor et al. have observed that irradiation requirements can be decreased when
both the amount of bone marow injected and the length of anti-CDl54 mAb treatment
are increased (184). Amazingly, chimerism was obtained with only 1 Gy of TBI when 40
millon BALB/c bone marow cells and a two-week course of anti-CDl54 mAb were
used (184). Although chimerism levels were relatively low (24%), they could be
increased to 48% when 2 Gy of irradiation was used.
Another successful sublethal conditioning regimen utilized the injection of
splenocytes and anti-CDl54 mAb ten days prior to bone marrow transplantation (181).
The pre-exposure of alloreactive T cells to donor antigen (splenocytes) and anti-
CD154mAb, has been suggested to lead to the deletion of alloreactive T cells prior to
bone marow transplantation (120). As a result of this deletion prior to transplantation
only I Gy of irradiation was required for stem cell engraftment.
The injection of donor splenocytes is also involved in a protocol utilizing
splenocytes that have been irradiated and rendered apoptotic. Using 7 Gy of irradiation
along with the injection of apoptotic splenocytes (187), stable and long-term engraftment
of bone marow was observed. Interestingly, the origin of apoptotic splenocytes was not
restricted to the same origin as the bone marow as third pary or even human xenogeneic
splenocytes were capable of facilitating bone marow engraftment (187).
Recently, approaches have utilzed the combination of anti-CD154 mAb and
CTLA4-Ig to eliminate irradiation altogether. These protocols utilize immunosuppressive
or myeloablative reagents such as sirolimus in combination with anti-lymphocyte serum
(188) or busulfan (183) as a replacement for sublethal irradiation. Although irradiation is
eliminated from these conditioning regimens, the use of myeloablative drugs or T cell
depleting reagents may lead to a prolonged state of immune suppression similar to that of
sublethal irradiation.
Conditioning regimens that can induce allogeneic bone marrow engraftment
without the use of irradiation, immunosuppression or myeloablative drugs have recently
been described (179). Wekerle et al. have obtained hematopoietic chimerism in C57BL/6
recipients with a single injection of 200 millon B lOA bone marow cells combined with
anti-CDl54 mAb and CTLA4-Ig (179, 182). This protocol is by far the least toxic of all
the protocols described, but the exceptionally high dose of bone marow that was
necessary for engraftment (200 million cells) is unlikely to be available from human bone
marow donors (189). A second drawback is the close genetic similarties between
C57BL/6 and BlOA mice, which are similar in many of their non-MHC background
genes, a situation not found in the clinic unless donors are closely related famly
members.
A second conditioning regimen that induces bone marow engraftment in the
absence of irradiation or myeloablation has been described by Durham et al (182). This
protocol involves 8 injections of allogeneic bone marow and anti-CDl54 mAb over a
90-day period. This protocol induces chimerism in the majority of mice, but the levels of
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chimerism are extremely low (average of 6% donor-derived cells in PBMC).
Furthermore, the multiple injections over an extended time frame, would be a hindrance
in converting a similar protocol to human clinical trals.
These sublethal/non-myeloablative protocols have been initiated with the hope of
being less toxic to the recipient. Despite this, very little work has been performed to study
the safety and effcacy of these new sublethal approaches, especially with respect to
infection. Moreover, many of these protocols depend on the use of T cell depleting
reagents , which may result in a prolonged deficiency of T cells. As T cells typically clear
viral infections, the use of T cell-depleting antibodies could substantially increase the
risks of viral infection.
The central focus of this thesis work was to understand the implications of viral
infection during and after bone marow transplantation. We therefore sought to determne
the effect of viral infection on 1) the engraftment of allogeneic bone marrow, 2) the
induction of donor-specific tolerance and 3) the abilty of the host to clear the viral
infection. To do so, we created a sublethal conditioning regimen that induced
hematopoietic chimerism, based on costimulation blockade and sublethal irradiation.
E. Central tolerance induced b bone marow sublethal irradiation and anti-CD 154 mAb
Our laboratory s initial attempts to induce hematopoietic chimerism utilized
sublethal irradiation and anti-CDl54 mAb (190). This protocol involved two 0.5 mg
injections of anti-CD 154 mAb on days 0 (the day of bone marrow transplantation) and on
day +3. On day 0, recipients received 4 Gy of irradiation followed by a single injection of
twenty five millon C57BL/6 allogeneic bone marrow cells (190). This protocol
successfully induced stable and long-term chimerism in all recipient mice, with ::99% of
the PBMC of donor-origin. All chimeric mice demonstrated donor-specific tolerance by
accepting donor-origin skin allografts and promptly rejecting third-pary skin allografts.
Furthermore, no clinical evidence of GVHD was detected in any of the chimeric mice.
Interestingly, chimeric mice in these initial studies contained ::99% donor-origin
cells in their PBMe. The creation of a full chimera has several disadvantages over the
creation of a mixed chimera including impaired immunocompetence (2 191) and an
increase in the likelihood of GVHD (3 192). Based on these observations , one of the
initial goals of this thesis was to develop a protocol using sublethal irradiation and anti-
CD154 mAb capable of producing a state of mixed chimerism.
The second goal of this thesis was to determne whether viral infection could
interfere with the induction or maintenance of hematopoietic chimerism and donor-
specific tolerance. The species combination that we chose to use was BALB/c mice 
donors and C57BL/6 mice as recipients. We chose this combination initially, as the
converse donor-recipient combination led to the creation of full donor-origin chimeras.
Furthermore, the use of C57BL/6 mice as recipients provides two major advantages. The
first is the availability of varous targeted mutations in C57BL/6 mice, allowing us to
dissect the role of varous cell populations and cytokines. Secondly, the immune response
of C57BL/6 mice to LCMV infection is extremely well characterized.
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A. Introduction
LCMV has been intensely studied for over 65 years and is the prototype member
of the arenaviridae famly of viruses (193). The name Arenaviridae is derived from the
Latin word arenosus meaning sandy, due to the presence of host ribosomes inside the
virion that appear as electron-dense granules when viewed in the electron microscope
(194). This famly of viruses contains Old World viruses derived from Afrca and New
World viruses derived mostly from South America. LCMV, Lassa, Mopeia and Mobala
are examples of Old World viruses , whereas Junin , Machupo, Tacarbe, and Pichinde are
members of New World viruses.
Several different strains of LCMV have been isolated including Arstrong, Traub
and WE strains. Arstrong and Lilie first described the Arstrong strain of LCMV in
1934. After inoculating both monkeys and mice with cerebrospinal fluid from a patient
diagnosed with St. Louis encephalitis , they observed the development of lymphocytic
choriomeningitis (193). The Traub strain was discovered to produce a similar
choriomeningitis in colonies of Swiss mice (195). The WE strain was discovered in 1936
when an employee at the Rockefeller University died from an apparent hemorrhagic fever
after being exposed to a mouse infected with the Traub strain (196). Minor differences
exist between strains, especially with regards to the site of replication. The Armstrong
strain replicates mostly in the spleen and other lymphoid tissues, while the WE strain can
also replicate in internal organs such as the liver and lung (197).
B. Imune Response to LCMV
A typical LCMV infection in mice results in the activation of many components
of the immune system. Early after infection there is a potent induction of type IF (al3)
that peaks at day 2 post-infection (198). The release of IF-al3 helps fight off viral
infection by the production of 2' 5' oligo adenyl ate synthetase and RNAse L, which
degrade viral mRNA, and the induction of the protein kinase PKR, which blocks the
initiation of viral RNA translation (199). Type IF also induces the activation and
proliferation of NK cells, monocytes/macrophages and cytotoxic T cells as well as the
induction ofMHC class 1 antigens (199-201).
During the first four days of infection, LCMV also induces the activation and
accumulation of NK cells (201 202). Interestingly, depletion of NK cells does not
increase LCMV viral titers, suggesting that NK cells play only a minor role in LCMV
clearance (203). This may be related to the ability of type IF to upregulate the levels
of class 1 MHC expression on virally infected cells, as NK cells are capable of killng
cells that downregulate self MHC I expression (204 205).
During the early stage of LCMV infection, clonal expansion of T cells also
begins. CD8+ T cells expand to a greater extent than CD4+ T cells , resulting in the change
of CD4:CD8 T cell ratios from 2:1 , to as much as 1:3 by day 8-9 post-infection
(206 207). LCMV -specific CD8+ CTL become detectable by day 8-9 post-infection and
are very proficient at clearng LCMV (197). LCMV-specific CTL lyse LCMV-infected
targets through the release of perforin (208,209). These CTL develop without the need
for anyone paricular adhesion molecule, costimulatory molecule or cytokine, as LCMV-
specific CTL are generated in knockout mice that lack CD4+ T cells, NK cells, B cells,
CD2, CD54, CDl1a, CD154, IL- , IL- , or IF-y (210-218).
At the peak of the T cell response to LCMV (day 8-9), numerous activated B cells
and macrophages are also detectable (219,220). Mice depleted of B cells are able to clear
an LCMV infection, indicating that B cells playa minor role in LCMV clearance (211).
On the other hand, depletion of marginal zone macrophages led to an attenuated CTL
response and viral persistence, indicating that macrophages play some role in the
clearance of LCMV (221).
LCMV titers decrease 5 days after infection as LCMV 
-specific CD4 and CD8 T
cells increase in numbers (197). Due mostly to the action of LCMV-specific CD8+ CTL
viral titers and antigen rapidly decline. Once LCMV is cleared, activated T cells undergo
cell death, and T cell numbers and CD4:CD8 T cell ratios return to normal (222 223).
e. Three Outcomes of LCMV Infection
Three outcomes of LCMV infection can occur depending on the route of infection
and the age of infected mice. Mice infected with LCMV either in utero or shortly after
birth are unable to clear an LCMV infection, and as a result, become persistent carers of
the virus (224 225). Intracranial infection is associated with a fatal meningoencephalitis
which occurs 5-8 days after infection due to a massive infiltration of CD8+ T cells into
the brain (226). In normal healthy adult mice, LCMV is a relatively noncytopathic virus
(when infection occurs through a non-intracranial route). These mice are able to clear an
LCMV infection within 7- 10 days and thereafter maintain permanent immunity (227).
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Viral persistence, however, can occur in immunocompromised mice and 
thought to be the result of clonal exhaustion (103). According to this concept, there is a
period of time allowed for the immune system to clear the virus in order to safeguard the
host from virus-induced pathology. Healthy mice clear LCMV within this time frame.
However, when viral replication is extremely high, the immune system may be unable to
clear the virus in time, resulting in clonal exhaustion, the elimination of the T cell
response and persistent viremia (197).
D. Safet and Effcac : LCMV and Bone Marrow Trans lantation
As mentioned above, viral infection is a major cause of human mortality and
morbidity following allogeneic bone marow transplantation (149). Viral infections have
been implicated in allograft rejection, the enhancement of GVHD, and the loss of graft
function (6 228-230).
Viral infections have the potential to disrupt bone marow transplantation through
several mechanisms. One mechanism is the induction of IF-y, a cytokine potently
induced by LCMV and many other viruses (202). IF-y can directly suppress bone
marow growth (231). IF- Y can also induce the activation and proliferation of NK cells,
which are capable of rejecting allogeneic bone marow grafts (202 232-234).
second mechanism is the ability of viruses to induce T cell growth and
differentiation factors. The increase in CD8+ T cell numbers over CD4+ T cells could
have dramatic effects on either the induction or maintenance of tolerance. We have
previously shown that CD4+ T cells are necessary for both the initiation and maintenance
of tolerance induced by our two-element protocol of DST and anti-CDl54 mAb (117).
Additionally, the production of cytokines such as IL-2 by the expanding T cell population
could potentially break a state of tolerance through bystander activation (98 235).
A third- mechanism is the abilty of many viruses to induce virus-specific CTL
that can lyse uninfected allogeneic targets (5 236 237). These cross-reactive CTL have
the potential to lyse uninfected donor bone marow cells, thus preventing bone marow
engraftment.
With respect to allogeneic bone marrow transplantation usmg costimulation
blockade, there is one additional concern of viral infection in regard to safety and
efficacy. Tolerance induction protocols based on costimulation blockade are based on the
exposure of alloantigen under conditions where T cells receive signal 1 (TCR/C-Ag)
without signal 2 (costimulation). The inabilty to receive signal 2 leads to the inactivation
of alloreactive T cells and loss of donor-specific immunity. Similarly, a viral infection at
the time of tolerance induction may induce tolerance to viral antigens, preventing an
immune response against the invading virus.
Recently, we have tested whether acute LCMV infection can interfere with the
induction of transplantation tolerance induced by our two-element protocol of DST and
anti-CDl54 mAb (238). Interestingly, the timing of LCMV infection relative to skin
grafting was the major determnant of skin allograft survival. Combined treatment of
DST and anti-CD154 mAb in uninfected thymectomized C57BL/6 recipients greatly
enhanced the survival of donor skin allografts (MST ;:308 days). In contrast, similarly
treated mice that were infected with LCMV I day after transplantation uniformly rejected
their grafts (MST=26 days). Delaying LCMV infection had a beneficial effect on skin
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? t allograft survival, as infection on day 15 (MST=78 days) and day 29 (MST=104 days)
after transplantation showed progressively longer skin allograft survival. Mice infected
with LCMV 51-57 days after transplantation had skin allograft survival (MST 237 days)
similar to controls (MST 251 days) (238). Therefore, in this model of transplantation
tolerance, LCMV was able to prevent both the initiation and maintenance of tolerance.
Based on these observations , we were concerned that an acute LCMV infection
would interfere with the induction and maintenance of hematopoietic chimerism and
transplantation tolerance induced by sublethal conditioning, costimulation blockade and
allogeneic bone marow. In order to examne the threat of viral infection, this thesis work
had two initial goals. The first goal was to create a conditioning regimen capable of
producing mixed allogeneic hematopoietic chimerism using sublethal irradiation and
costimulation blockade. Our second goal was to determne whether LCMV infection
could interfere with either the induction or maintenance of hematopoietic chimerism and
donor-specific tolerance.
METHODS
1. Animals
Female C57BL/6 (H2 , Ly5.2), C57BL/6-Ly5. 1, CBA/JCR (H2 ) and BALB/c
(H2 ) mice were obtained from the National Cancer Institute, Frederick, MD. 129/Sv
wild-type (H2 ) and SVl29 interferon-al3 receptor knockout mice (216) were obtained
from a colony maintained at the University of Massachusetts Medical SchooL C57BL/6
mice in which the CD4, CD8 , TCR-al3 or TCR-yo gene was disrupted by homologous
recombination were obtained from The Jackson Laboratory (Bar Harbor, ME). All
animals were certified to be free of Sendai virus, pneumonia virus of mice, murine
hepatitis virus, minute virus of mice, ectromelia, LDH elevating virus, mouse poliovirus
Reo- virus, mouse adenovirus, LCMV, polyoma Mycoplasma pulmonis and
Encephalitozoon cuniculi. All animals were housed in an SPF facility in microisolator
cages and given ad libitum access to autoc1aved food and acidified water. They were
maintained in accordance with the guidelines of the Institutional Animal Care and Use
Commttee (IACUC) of the University of Massachusetts Medical School and
recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council, National Academy of
Sciences, 1996).
2. Antibodies and Flow Cytometry
Clone MR1 hamster anti-mouse CDl54 mAb (70) was produced as ascites in scid
mice and purified by Protein A affinity chromatography (Amersham Pharacia Biotech
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, Uppsala, Sweden). Antibody concentration was determned by measurement of
optical density and confirmed by ELISA as described previously (239). The
concentration of contaminating endotoxin was determned commercially (Charles River
Endosafe, Charleston, SC) and was uniformy -=10 units EU per mg of mAb. Mice
received two 0.5 mg injections given intraperitoneally (i.p.). The first injection was made
on the day of bone marow transplantation (day 0) and the second injection was given 3
days later (day +3). Depleting antibodies were used according to the following schedules:
Anti-NK1.1 mAb (PK- 136 (240)) 1 mg i.p. on days -
, -
, +6; anti-CDl22 mAb (TM-131
(241-243)) 1 mg i.p. on day - I; anti-asialo-GMI (ascites) 100 ul i.p. on days - , +4; anti-
CD4 mAb (GK1.5) and anti-CD8 mAb (2.43) 0.5 mg i.p. on days -3, -2 and-
, FIC-conjugated anti-H2- (AF6-88.5) and anti-Ly5. (104) mAbs, PE-
conjugated anti-H2- (SFl- 1.1), anti-Ly5. 1 (A20), anti-CD4 (L3T4), anti-CD8a (53-
7), anti-TCR 13 chain (H7-597), anti-CD45R/220 (RA3-6B2), anti-CDllb/Mac1
(Ml/70), anti-NK1.1 (PK136) and anti-GRI (RB6-8C5) mAbs , and biotinylated anti-H2-
(SFl- l.l) and anti-Ly5. 1 (A20) mAbs were all obtained from Pharngen (San
Diego, CA). Flow cytometry was performed as described (190). Briefly, single cell
suspensions were labeled with antibody, rinsed, washed, fixed in 1% paraformaldehyde
and analyzed on a FACScanCI (Becton Dickinson, Sunnyvale , CA). Forward angle and
side scatter properties were used to distinguish lymphocytes, monocytes and
granulocytes. Dead cells and erythrocytes were excluded by electronic gating. At least
events were analyzed for each sample. The relative percentages of host- and donor-
origin cells in the C57BL/6 (H2- , Ly5.2) recipients of BALB/c (H2- ) or C57BL/6-
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Ly5. 1 (Ly5. 1) bone marrow were determined by flow cytometry. In preliminary
experiments , known mixtures of donor and host peripheral blood mononuclear cells were
analyzed, and it was determined that the lower limit of sensitivity of the assay for
detecting either donor (H2- or Ly5. 1) or host (H2- or Ly5.2) cells was 0.5%.
Because not all hematopoietic cells express MHC class I antigen, the relative percentage
of donor-origin cells in chimeric mice recipients was calculated as follows: (% donor
cells + (% donor cells + % host cells)) x 100 (190).
3. Cell Preparation and Bone Marrow Transplantation
Recipient mice were treated with 6 Gy whole body irradiation using a 13 
source (Gamacell 40, Atomic Energy of Canada, Ottawa, ON, Canada). This dose was
documented in preliminary experiments to be non-lethal for C57BL/6 mice. Within 1-
hours of irradiation all recipients received a single intravenous (i.v.) injection of 18-25 x
donor bone marow cells in a volume of 0.5 ml via the lateral tail vein. Donor femora
and tibiae (female BALB/c or C57BL/6-Ly5. 1 mice at least 6 weeks of age) were flushed
with RPMI medium using a syringe with a 24-gauge needle. Recovered cells were
fitered through sterile nylon mesh (70 /lm Becton Dickinson, Frankn Lakes, NJ),
counted, and re-suspended in RPMI. Recipient mice were females at least 6 weeks of age.
To assess levels of chimerism, blood samples were obtained from mice that had received
donor bone marow 2 to 4 weeks earlier. Additional blood samples were obtained
periodically as described in the Results. Hematopoietic chimerism was defined as the
presence of ::1.0% MHC class r donor-origin cells in the blood.
Single cell suspensions of spleen cells were fitered through sterile nylon mesh
(70 /lm), centrfuged, and erythrocytes were lysed with hypotonic Cl. The cells were
then resuspended in RPMI and counted in the presence of crystal violet using a
hemocytometer.
4. LCMV Infection and Assay for Infectious Units of LCMV
Mice were inoculated i.p. with 5 x 10 plaque formng units (PFU) of LCMV
strain Arstrong, propagated in baby hamster kidney cells (238). Mice were inoculated
with LCMV immediately after bone marow injection, or 2 or 7 weeks post-
transplantation as described in the text.
LCMV viral titers were measured by LCMV viral plaque assays (244). Results
are expressed as geometric mean titers, e. the arthmetic mean of the 10glO values.
5. Circulating Levels of IFN-al3
NCTC-929 cells were incubated overnight in 96-well plates with 2-fold dilutions
of peripheral blood. These mixtures were then infected with vesicular stomatitis virus
(VSV), incubated for 3 days and examined in order to determne the last dilution of
peripheral blood that prevented VSV -induced cytotoxicity. Estimates of units/mL were
based on the addition of known quantities of purified IF-al3 to NCTC-929 cells , prior to
infection with VSV.
6. Skin Transplantation
Full thickness skin grafts -1 cm in diameter were obtained from shaved donors
scraped to remove muscle, and grafted without suturing onto prepared sites on the flanks
of anesthetized recipients. Skin grafts were dressed with Vaseline impregnated gauze
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and an adhesive bandage for the first 7 days after surgery. Thereafter, skin grafts were
assessed 3 times weekly, and rejection was defined as the first day on which the entire
graft surface appeared necrotic (245). Because we have previously determned that fully
allogeneic skin grafts placed on untreated recipients typically survive for 10- 12 days
(246), grafts that were adherent to the bandage or fully necrotic on day 7 were deemed
technical failures and were excluded from analysis.
7. Histology
Samples of transplanted skin, host skin, small intestine, large intestine, femur
spleen, and liver were recovered from selected experimental mice, fixed and stored in
10% buffered formalin, embedded in paraffn and processed for light microscopy.
Sections for routine light microscopy were stained with hematoxylin and eosin. A
qualified pathologist, who was unaware of the treatment status of specimen donors,
performed histological analyses.
8. Statistical Analysis
Parametrc data are presented as the arthmetic mean:! one standard deviation.
Average duration of graft survival is presented as the median survival time (MST). Graft
survival among groups was compared using the method of Kaplan and Meier (247); the
equality of allograft survival distributions for animals in different treatment groups was
tested using the log rank statistic (248). P values -:O.OS were considered statistically
significant. Comparsons of proportions in 2 x 2 tables used the Fisher exact statistic
(249).
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CHAPTER I
SUBLETHAL IRRADIATION AND ANTI-CDI54 ANTIBODY LEADS TO
LONG- TERM AND STABLE MIXED HEMATOPOIETIC CHIMERISM AND
DONOR-SPECIFIC TRANSPLANT A TION TOLERANCE
INTRODUCTION CHAPTER I
Human hematopoietic stem cell (HSC) transplantation has required lethal whole
body irradiation and immunosuppression. These conditioning regimens have permtted
stem cell engraftment and lowered the incidence of rejection , but there are a number of
severe side effects associated with this therapy. These negative side effects include the
induction of severe neutropenia that leads to a high rate of infections, the need for chronic
immunosuppression, the failure of this chronic immunosuppression to prevent chronic
GVH , and the high incidence of neoplasia due to the chronic immunosuppression (1).
These side effects restrct this therapy to patients who suffer from lethal malignancies or
hematological diseases. Furthermore, stem cell transplantation using lethal irradiation
typically produces a state of full donor chimerism, which is associated with decreased
immune reactivity (2) and an increase in GVHD (3) compared to a state of mixed
chimerism.
In order to overcome these problems, newer approaches to hematopoietic stem
cell transplantation have focused on less toxic approaches, paricularly sublethal
conditioning regimens that do not rely on the use of chronic immunosuppression. These
conditioning regimens hope to reduce the length and severity of neutropenia associated
:;:
with stem cell transplantation, thereby reducing the risk of infection. The lack of need for
chronic immunosuppression would also decrease the risk of developing neoplasia.
Another goal of sublethal conditioning regimens is to allow this therapy to be used for
non-lethal malignancies, autoimmune disease and organ transplantation.
One approach to induce hematopoietic chimerism is the use of costimulation
blockade. Costimulation blockade of T cell activation has been found to facilitate the
engraftment and establishment of allogeneic hematopoietic chimerism (4). This approach
has been used to successfully establish mixed hematopoietic chimeras in mice, while also
significantly reducing the toxicity of the conditioning regimens (4). The goal of this
chapter is to utilize costimulation blockade and sublethal irradiation in order to achieve
stable mixed hematopoietic chimerism in the absence of GVHD and with minimal
conditioning to the host.
;d",
RESULTS CHAPTER I
1. Stable engraftment of BALB/c bone marrow into C57BL/6 recipients requires 6
Gy of irradiation
We first determned how much irradiation was necessary to induce allogeneic
hematopoietic chimerism in C57BL/6 recipient mice. Mice were injected intravenously
with a single dose of 18-25 millon allogeneic BALB/c bone marow cells immediately
after receiving 3-7 Gy of irradiation, as depicted in Figure 4. Experimental mice were
next split into two groups, one of which received two 0.5 mg injections of anti-CDl54
mAb. The first of these injections was given on day 0, the day of transplantation, whereas
the second injection was given on day +3, three days after bone marrow transplantation.
The second group of experimental mice received no further treatment. The amount of
bone marow cells used in these experiments as well as the timing and dose of anti-
CD154 mAb was previously optimized in our laboratory (190). Flow cytometry was
performed at 2-4 weeks on peripheral blood mononuclear cells (PBMC) in order to
determne the level of donor and host-derived cells using MHC class I markers (H2 vs.
The results, as shown in Table 1, document that at least 5 Gy of irradiation was
necessary for allogeneic bone marow engraftment. Mice that received 3-5 Gy of
irradiation contained undetectable levels of donor-origin cells in their PBMC, irregardless
of whether they received anti-CDl54 mAb or not. The one exception was a single
chimeric mouse (28% donor-derived cells in PBMC) in the group treated with 5 Gy and
anti-CDl54 mAb. Mice that received 6 Gy of irradiation required anti-CDl54 mAb for
i: ;
engraftment. The majority of mice (67% , N=9) treated with anti-CDl54 mAb became
chimeric with an average of 68% donor-origin cells in their PBMC, whereas none of the
5 mice that did not receive anti-CDl54 mAb became chimeric. Finally, all mice that
received 7 Gy of irradiation (N=5) became chimeric regardless of whether or not they
received anti-CD154 mAb. However, mice treated with 7 Gy without anti-CD154 mAb
expressed low levels of chimerism (27%) which disappeared withn 7 weeks of
transplantation. In contrast, mice that received 7 Gy and anti-CDl54 mAb contained
much higher levels of donor-origin cells (90%) and chimerism was stable throughout the
7 weeks of observation. Given that our goal was to minimize the conditioning of our mice
while maintaining a high percentage of chimeric mice, all future experiments were
conducted with 6 Gy of irradiation and anti-CDl54 mAb.

Legend to Figure 4: This figure schematically depicts our protocol for bone
marow transplantation using sublethal irradiation and costimulation blockade. C57BL/6
mice were injected intravenously with a single dose of 18-25 millon allogeneic BALB/c
bone marow cells immediately after receiving 3-7 Gy of irradiation. Experimental mice
also received two 0.5 mg injections of anti-CD 154 mAb. The first of these injections was
given on day 0, the day of transplantation, and the second injection was given on day +3
three days after bone marow transplantation.
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Legend to Table 1: C57BL/6 mice were irradiated with 3-7 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of 18-25 x 10 BALB/c
donor bone marow cells in a volume of 0.5 ml via the lateral tail vein. As indicated, anti-
CDl54 mAb (0.5 mg) was injected intraperitoneally on the day of irradiation and on day
+3. The percentage of H2 donor-origin peripheral blood mononuclear cells (PBMC) was
determned by flow cytometry 2-4 weeks after irradiation. Chimerism was defined as the
presence of ).1 % MHC class 1+ donor-origin cells two weeks after transplantation. Only
mice that remained chimeric were used to determne the percentage of donor-origin cells.
Mice that contained undetectable levels of donor-derived cells are listed as having -:1 %
as the lowest level of chimerism detectable by our system was 0.5%. Each data point
represents the arthmetic mean :t 1 standard deviation (s.
2. Stable and long-term engraftment of BALB/c bone marrow into C57BL/6
recipients treated with 6 Gy requires anti-CDl54 mAb
We next sought to determne the durability of hematopoietic chimerism induced
by 6 Gy of irradiation , and whether the engraftment of allogeneic bone marow differed
from syngeneic bone marow at this irradiation dose. C57BL/6 (H2 ) mice received 6 Gy
. .
of irradiation and were injected intravenously with 18-25 millon bone marow cells from
either syngeneic C57BL/6-Ly5. 1 or fully allogeneic BALB/c donors. These mice were
than split into groups that either received two 0.5 mg injections of anti-CD154 mAb or
received no further treatment.
As shown in Table 2 , the addition of anti-CDl54 mAb treatment was not required
for the generation of syngeneic hematopoietic chimerism and had no effect on the
percentage of syngeneic donor-origin cells that engrafted. In contrast, mice that received
allogeneic BALB/c bone marrow cells plus 6 Gy of irradiation once again failed to
become chimeric in the absence of anti-CDl54 mAb. However, when two 0.5 mg doses
of anti-CDl54 mAb were added to the conditioning regimen, the majority (9 of 14
recipient mice) developed mixed hematopoietic chimerism 2 weeks after transplantation.
In order to determne both the stability and duration of chimerism in these mice
flow cytometry was performed at intervals up to 27 weeks after transplantation. Two
allochimeric mice lost chimerism within 7 weeks of transplantation and 2 additional
allochimeric mice were removed from the study for histological analysis. In the
remaining 5 allochimeric mice , the percentage of donor-origin cells remained stable and
high throughout the 27 weeks of observation. All 15 of the mice (100%) that received
! i
syngeneic bone marow , regardless of whether they received anti-CDl54 mAb or not,
became chimeric and remained chimeric throughout the 27 week period of observation.
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Legend to Table 2: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of 18-25 x 10 donor
bone marow cells in a volume of 0.5 ml via the lateral tail vein. Anti-CD154 mAb (0.5
mg) was injected intraperitoneally on the day of irradiation and on day +3. The
percentage of H2 or Ly5. 1 donor-origin PBMC was determned by flow cytometry 2-
weeks after irradiation. Chimerism was defined as the presence of 0% MHC class 
donor-origin cells two weeks after transplantation. All mice with -:1.0% donor-origin
cells at the two week time point had -:1.0% donor cells at all other time points. Only mice
that remained chimeric were used to determne the percentage of donor-origin cells. Each
data point represents the arthmetic mean:! I s.d. In cases where mice were removed
from the experiment for histological analysis , the number of animals tested at each time
point is given in parentheses. a: one mouse was killed at this time point for histology; b: 2
mice were no longer chimeric at this time point, and one additional chimeric mouse was
killed at this time point for histology.
3. Blockade of the CD140-CD154 pathway prevents GVHD in allogeneic
hematopoietic chimeras
Graft versus host disease (GVHD) is a problematic side effect associated with
bone marow transplantation. In order to determne whether our protocol of sublethal
irradiation and anti-CD 154 mAb treatment prevented the development of GVHD, we
electively killed 1 synchimeric mouse 7 weeks post transplantation and 2 allochimeric
mice 2 and 7 weeks post transplantation. Histological examnation of skin, liver, as well
as the small and large intestine in all 3 of these mice revealed no evidence of GVHD.
Furthermore, there was no histological evidence of GVHD at the time mice were
electively killed, up to 340 days after bone marrow transplantation.
4. Allogeneic and syngeneic hematopoietic chimeras display multi-lineage chimerism
The S stable allochimeric mice shown in Table 2 were also analyzed by flow
cytometry to determne the phenotype of donor cells that exist in the PBMC of our
chimeric mice. To do so, the percentage of donor-origin T cells, B cells, macrophages
and granulocytes present in their peripheral blood was determned. As shown in Figure
, donor-origin cells representing each of these 4 lineages were present in allochimeric
CS7BL/6 recipients throughout the 9-week period of observation. The percentage of
donor-origin T and B cells rose over time , whereas the percentage of donor-origin
granulocytes was maximal 2 weeks after transplantation and declined thereafter. As
expected, donor-origin cells representing all 4 lineages were also present in syngeneic
chimeric recipients (Figure SB) and exhibited the same temporal changes in percentage as
their allogeneic counterparts.
Figure 5. Multi-lineage analysis of hematopoietic chimeras
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Legend to Figure 5: The 5 stable allochimeric mice and 10 synchimeric mice
shown in Table 2 (lines 4 and 2 respectively) were analyzed by flow cytometry at 2, 4, 7
and 9 weeks post transplantation, as described in Methods. The percentage of donor-
origin T cells, B cells , macrophages, and granulocytes present in their peripheral blood
was determned by using appropriate fluorescent-labeled markers. Each data point
represents the mean:! I s.
. "
,-,l'
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5. Donor-specific skin grafts survive indefinitely on allogeneic and syngeneic mixed
chimeras
Having generated stable and long-term mixed hematopoietic chimerism in the
absence of GVHD, we next determned whether donor-specific tolerance had been
induced in our chimeric mice. To do so, a total of 20 C57BL/6 mice received BALB/c
skin grafts 8 to 17 weeks after transplantation of BALB/c bone marow. Among these
bone marow recipients , 9 had been conditioned with sub-lethal irradiation without anti-
CD154 mAb treatment and were non-chimeric. The median survival time (MST) 
donor skin grafts in these non-chimeric mice was short (Figure 6B , MST=12 d, range 10-
12 d). The remaining 11 mice had been conditioned with sub-lethal irradiation, as well as
anti-CDl54 mAb as described above, and at the time of skin grafting all were chimeric.
The percentage of donor-origin PBMC in these recipients was 58 to 96%. All 11 skin
grafts were stil intact at the time these allochimeric animals were electively killed 72 to
251 days after transplantation. This skin graft survival was significantly longer than that
which was seen for the 9 mice that did not receive anti-CDl54 mAb and did not become
chimeric (p.:O.OOl vs. allochimeric recipients).
Histological analysis of transplanted skin was performed on a subset of 2 chimeric
mice with healed-in BALB/c skin grafts that had survived intact for 205 and 212 days. In
neither instance was there evidence of inflammation suggestive of graft rejection.
As expected, the donor-specific (C57BL/6-Ly5. 1) skin grafts on chimeric
C57BL/6 recipients of syngeneic C57BL/6-Ly5. 1 bone marow survived indefinitely
(Figure 6A). This was tre both for recipients conditioned with irradiation alone
(MST=138 , Range 32- 164 days , N=5) and for recipients conditioned with both irradiation
and anti-CDl54 mAb (MST=156, Range 60-297 days , N=23).
Figure 6.
Skin graft survival on hematopoietic bone marrow chimeras
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Legend to Figure 6: C57BL/6 mice received 6 Gy of irradiation and 2 injections
of anti-CD154 mAb (days 0 and +3). Mice also received 25 millon bone marow cells
from either syngeneic (C57BL/6-Ly5. 1) or allogeneic (BALB/c) donors. Eight to 17
weeks after transplantation mice were given a donor-specific or third pary skin graft as
described in Methods. Mice that received BALB/c bone marow were transplanted with
BALB/c and CBA/JCr skin grafts, whereas mice that received C57BL/6-Ly5. 1 bone
marow were transplanted with C57BL/6-Ly5. 1 and CBA/JCr skin grafts. Skin graft
survival was measured and quantified using median survival time (MST) and presented
using the method of Kaplan and Meier.
;r.
6. Third party skin grafts are promptly rejected on allogeneic chimeras
After documenting that our chimeric mice were tolerant to donor-specific skin
grafts, we next determned whether this tolerance was donor-specific by transplanting
third pary skin grafts onto our chimeric mice. Three allochimeric mice with healed-
donor-specific (H2 ) skin grafts that had been in place for 30 days were selected at
random and given a third pary CBA/JCR (H2 ) skin graft on the contralateral flank.
Survival of the CBA/JCr skin allografts was brief (Figure 6, MST=l1 days , range 10-
days). The BALB/c skin grafts on these mice were stil intact at the conclusion of the
experiment; 127 days after the CBA/JCr skin allografts had been rejected. One additional
allochimeric mouse received only a CBA/JCr skin allograft, and survival of that graft was
brief (MST=l1 days). These data demonstrate that T cell function was present in our
allochimeric mice and that they were specifically tolerant to H2 -expressing cells.
7. Chapter I Summary
The data described in this chapter documents a model system characterized by
mixed hematopoietic chimerism and donor-specific central tolerance. Chimeric mice
both allogeneic and syngeneic, displayed stable and long-term multi-lineage chimerism.
They also permanently accepted donor-specific skin grafts while maintaining the ability
to promptly destroy third pary skin grafts. Mixed hematopoietic chimerism was obtained
in the absence of GVHD and with minimal preparative risk to the recipient. Because this
system of inducing hematopoietic chimerism accurately models an approach that could
be used in the clinic , it was deemed appropriate for use in analyses of safety and
durabilty in the presence of viral infection, a common complication of clinical bone
marow transplantation.
CHAPTER II
LCMV INFECTION AT THE TIME OF ALLOGENEIC BONE MARROW
TRANSPLANTATION LEADS TO GRAFT REJECTION AND HOST DEATH
INTRODUCTION CHAPTER II
Having established stable mixed hematopoietic chimerism usmg sublethal
irradiation and costimulation blockade, we next sought to determne whether viral
infection could interfere with either the induction or maintenance of hematopoietic
chimerism and donor-specific tolerance in our model system. Many viral infections can
induce inflamatory cytokines (232), T cell growth and differentiation factors and virus-
specific CTL that react to allogeneic targets (S), any of which could potentially
compromise graft survival and overcome tolerance. Furthermore, recipient mice treated
with parial myeloablation combined with costimulation blockade could be less resistant
to viral infection and its associated pathophysiological effects. Therefore, the experiments
in this chapter focus on the safety and efficacy of our conditioning regimen with regard to
viral infection. LCMV was chosen as the model virus for these studies, as it induces all of
the attrbutes of viral infection listed above. Additionally, LCMV is one of the most well
studied viral pathogens, paricularly in the CS7BL/6 mice.
;"" : ,
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RESUL TS CHAPTER 
1. LCMV infection does not interfere with the induction or maintenance of
syngeneic hematopoietic chimerism
In order to determne whether viral infection could interfere with either the
induction or maintenance of hematopoietic chimerism in our model system, CS7BL/6
mice were randomized into two groups and treated with irradiation, anti-CDlS4 mAb
and either syngeneic CS7BL/6-LyS. l or allogeneic BALB/c bone marow, as shown in
Figure 7. The transplanted mice in both groups were then randomly assigned to one of
four sub-groups. The first sub-group received no further treatment. Mice in the remaining
three sub-groups were given an intraperitoneal injection of LCMV, strain Arstrong, on
the same day as transplantation, or on day IS or day SO after transplantation.
As shown in Table 3, there was no effect of LCMV infection at any time point on
the recipients of syngeneic CS7BL/6-Ly5. 1 bone marow with respect to the number of
mice becoming chimeric or the percentage of donor-origin cells present 2-9 weeks afer
transplantation. The percentage of donor-origin cells at each time point was comparable
to that observed in the uninfected control mice (Table 2, line 2). None of the mice in any
of the 4 syngeneic groups appeared sick or died during the period of observation.

Legend to Figure 7: This figure schematically depicts our protocol for
transplanting allogeneic bone marow into LCMV-infected mice, using sublethal
irradiation and costimulation blockade. C57BL/6 mice were injected intravenously with a
single dose of 18-25 million allogeneic BALB/c bone marow cells immediately after
receiving 6 Gy of irradiation. Experimental mice also received two 0.5 mg injections of
anti-CD154 mAb. The first of these injections was given on day 0, the day of
transplantation, and the second injection was given on day +3, three days after bone
marow transplantation. Finally, mice received an i.p. injection of LCMV, strain
Arstrong, either on the day of transplantation or 15 or 50 days after transplantation.
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Legend to Table 3: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of 18-25 x 10 donor
bone marow cells in a volume of 0.5 ml via the lateral tail vein. Anti-CD154 mAb (0.
mg) was injected intraperitoneally into all mice on the day of irradiation and on day +3.
Mice were injected on the days indicated with 5 x 10 PFU of LCMV, strain Armstrong,
as described in Methods. The percentage of H2 or Ly5. 1 donor-origin peripheral blood
mononuclear cells was determned by flow cytometry 2-9 weeks after bone marrow
transplantation. Chimerism was defined as the presence of ::1 % MHC class r donor-
origin cells two weeks after transplantation. The one mouse with -:1 % donor-origin cells
at the two week time point had -:1% donor cells at all other time points. All mice
chimeric at week 2 remained chimeric throughout the duration of the experiment. Each
data point represents the mean :t 1 s.d. *Three additional mice in this cohort died on day
, before they could be tested for chimerism.
''',;.
2. LCMV infection at the time of transplantation abrogates the induction of
allogeneic hematopoietic chimerism and is fatal
In contrast to the results seen with syngeneic bone marow, all C57BL/6
recipients of allogeneic BALB/c bone marrow that were infected with LCMV
immediately after transplantation died 13- 18 days after transplantation and infection
(N=15). Among these 15 mice, 12 survived long enough to be tested for chimerism on
days 12-13. No peripheral donor-origin cells were detectable in any of these mice (Table
3), indicating that a day 0 LCMV infection can block the development of allogeneic
hematopoietic chimerism.
In a separate experiment, C57BL/6 mice treated with 6 Gy, anti-CDl54 mAb and
given an allogeneic bone marow transplant were tested for chimerism at time points
immediately after bone marow transplantation and LCMV infection. No donor-origin
cells were found in the PBMC of LCMV-infected mice on days 1 , 4 or 7 post-
transplantation, suggesting that injected allogeneic bone marow cells never engraft as
opposed to donor cells initially engrafting and then being destroyed.
3. LCMV infection does not interfere with the maintenance of allogeneic
hematopoietic chimerism
We next determned the durability of our chimeric state by delaying LCMV
infection until 2 or 7 weeks after the establishment of mixed allogeneic hematopoietic
chimerism. Among the 10 mice randomized to receive LCMV 15 days after
transplantation, one died before infection. The remaining 9 mice were all chimeric on the
day before infection. Subsequent to infection, the percentage of donor-origin PBMC
declined by 17% on day 28 and remained at approximately this same level on days 49
and 63. None of these mice appeared il and none died. At each time point after infection
the percentage of donor-origin PBMC in the LCMV-infected mice (Table 3) was
somewhat lower than in the uninfected controls (Table 2, Line 4). These results suggest
that the deleterious effects of LCMV infection on host and graft survival are confined to a
narow window of time immediately after the tolerization and transplantation process.
Among the 10 mice randomized to receive LCMV 50 days after transplantation, 9
were chimeIic on the day before infection. Subsequent to infection, the percentage of
donor-origin PBMC in the chimeric mice declined by - 11 % on day 63. None of the 10
mice appeared il and none died. At corresponding time points after infection, the
percentage of donor-origin PBMC in the LCMV-infected mice (Table 3) was once again
lower than in the uninfected controls (Table 2, Line 4).
4. Clearance kinetics of LCMV in infected hematopoietic chimeras
j -
We next hypothesized that the differential survival of syngeneic vs. allogeneic
bone marow recipients, infected with LCMV at the time of transplantation , was due to
differential ability to clear the LCMV virus. To test this hypothesis we measured LCMV
titers in the PBMC of infected chimeric mice at different times after transplantation. As
shown in Table 4, all recipients of allogeneic or syngeneic bone marow infected on the
day of transplantation failed to clear the LCMV virus during the first two weeks after
infection. Two weeks after transplantation and infection , viral titers were similar between
these two groups , suggesting that neither viral load per se nor ability to completely clear
virus was the determnant of differential survival.
Syngeneic chimeras infected IS days after transplantation were able to clear the
LCMV infection, whereas allogeneic chimeras infected at day IS became persistent
carers of virus. Both allogeneic and syngeneic chimeras infected with LCMV SO days
after successful bone marow transplantation cleared the LCMV infection within two
weeks.
Table 4. Viral titers in the serum of allogeneic and syngeneic hematopoietic
chimeras infected with LCMV
Virus Titers (PFU/mL) Weeks
After LCMV Infectin
Donor Recipient Virus Infection 2wks 5wks 7wks
None C57BL/6 Day 0 3.5:t0. 8:tOA 8:t0.
BALB/c C57BL/6 Day 0 3:t0. dead
BALB/c C57BL/6 Day 15 8:tOA 2:tOA 3:t0.
BALB/c C57BL/6 Day 50
-(2
C57BL/6-Ly5. C57BL/6 Day 0 3A:t0. 3:tOA 8:t0.
C57BL/6-Ly5. C57BL/6 Day 15
-(2 -(2 -(2
C57BL/6- Ly5. C57BL/6 Day 50
-(2
Legend to Table 4: Serum from mice presented in Table 3 were assayed for
LCMV titers as described in Materials at 2-7 weeks after LCMV infection. Results are
expressed as geometrc mean titers e. the arthmetic mean of the 10gIO values.
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5. LCMV infection does not interfere with the maintenance of donor-specific
tolerance
After discovering that acute LCMV infection prevented the induction of
allogeneic chimerism, we next sought to determne whether LCMV infection could
interfere with the maintenance of donor-specific tolerance. Groups of C57BL/6 mice
were treated with 6 Gy of irradiation, anti-CDl54 mAb and given either allogeneic
BALB/c or syngeneic C57BL/6-Ly5. 1 bone marow. After testing for chimerism several
times to ensure that chimerism was durable, these mice were given donor-origin skin
grafts 89-109 days after bone marow transplantation. Immediately after skin grafting,
these mice were given an LCMV infection. Prior to skin grafting, the 8 allochimeric mice
contained a range of 63-90% donor cells, with the exception of a single mouse which
contained only 6%. Median survival time of the BALB/c skin grafts in these 9 mice was
greatly prolonged (MST=164 d, range 131-232 d), with the exception of the mouse that
contained only 6% donor cells. This mouse quickly rejected its skin graft (MST=14 d).
Unfortunately, chimerism was tested in this mouse two weeks prior to skin grafting but
not afterwards. Therefore, it is unkown whether this mouse had lost chimerism prior to
skin grafting.
Six stable syngeneic chimeras, with a range of 94-99% donor cells , were also
given an LCMV infection immediately after being transplanted with donor-origin skin
grafts (C57BL/6-Ly5. 1). Similar to the results seen in allogeneic chimeras, skin grafts on
these syngeneic chimeras had prolonged survival (MST=196 days , range 120-353 d).
"'.
-f.
Overall, these data indicate that LCMV infection does not interfere with the maintenance
of donor-specific tolerance in established hematopoietic bone marow chimeras.
6. Chapter II summary
In this chapter we have shown that in mice treated with irradiation, anti-CDl54
mAb and given an allogeneic bone marow transplant, LCMV infection can have a
dramatic effect on the survival of both the bone marow transplant and the recipient
mouse. C57BL/6 mice given a day 0 LCMV infection not only fail to become chimeric,
but also die shortly after bone marow transplantation. This result is all the more unusual
and interesting as it occurs after mice receive a sublethal dose of irradiation, and a viral
infection that is normally non-cytopathic. The lethal dose of irradiation in healthy
C57BL/6 mice is typically 10- 11 Gy of irradiation (personal observations). Therefore, the
6 Gy of irradiation used in these experiments is well below the lethal dose for C57BL/6
mice. Moreover, the Arstrong strain of LCMV that was used in these studies is
normally non-lethal when given as an i.p. injection, even when infection occurs in
immunocompromised C57BL/6 mice. Somehow, the combination of irradiation and a day
o LCMV infection triggers the rejection of the allogeneic bone marow transplant and the
death of the recipient. Fortunately, both mortality and the destruction of the bone marow
transplant are confined to a narow window of time immediately following
transplantation.
CHAPTER III
VIRAL ABROGATION OF STEM CELL TRANSPLANTATION TOLERANCE
CAUSES GRAFT REJECTION AND HOST DEATH BY DIFFERENT
MECHANISMS: A RADIORESISTANT CD8+TCR-al3+ NK1.r T CELL
POPULATION AND VIRUS-INDUCED INTERFERON-wl3
INTRODUCTION CHAPTER III
We have shown in chapter II that LCMV infection, at the time of transplantation
had severe consequences for the survival of the allograft and the host. Mice that received
6 Gy of irradiation, anti-CD154 mAb and an LCMV infection at the time of allogeneic
bone marow transplantation failed to engraft BALB/c bone marow and died 2-3 weeks
after transplantation. The inabilty of these mice to clear the LCMV virus was not
associated with allograft rejection or death. Therefore, we focused on the varous cell
populations that are activated and the cytokines that are induced following LCMV
infection. Both NK cells and CD8+ T cells dramatically increase shortly after LCMV
infection (197). Furthermore, both cell populations have been implicated in allograft
rejection (180 232). Additionally, cytokines such as IF-yand IF-al3 are induced by
LCMV infection and have been associated with hematopoietic stem cell suppression
(197 250 251). Based on these reports, this chapter analyzed the role of NK and T cells
as well as IFN-y and IF-al3 in allograft rejection and death in our recipient mice.
RESULTS CHAPTER III
1. Mouse fatality is dependent on the presence of allogeneic bone marrow
Our initial goal was to determne the mechanism(s) responsible for the mortality
of C57BL/6 mice that received allogeneic bone marow, 6Gy of irradiation, anti-CD154
mAb, and a day 0 LCMV infection. Initially, we asked why mice that received our
conditioning regimen along with syngeneic bone marow survived whereas recipients of
allogeneic bone marow died. In order to answer this question, we tested whether
mortality was due to a deleterious effect of allogeneic bone marow or whether our
conditioning regimen itself was lethal to C57BL/6 recipients.
Groups of C57BL/6 mice were treated with one or more of the following pars of
our conditioning regimen: 6 Gy of irradiation, two 0.5 mg injections of anti-CD 154 mAb
an allogeneic bone marow transplant or an LCMV infection. The results , shown in Table
, indicate that 6 Gy of irradiation by itself (Group 1 , 100% survival at 4 weeks, N=5) or
in combination with anti-CDl54 mAb (Group 2, 100% , N=5) does not cause mortality in
C57BL/6 mice. When 6 Gy of irradiation was combined with an LCMV infection, the
majority of mice once again survived (Group 3, 89%, N=9). Mice that received
irradiation, anti-CDl54 mAb and an LCMV infection had a slightly lower rate of
survival, as only 13 of 19 mice (Group 4, 68%) survived. In contrast to all other groups,
the vast majority of mice died when given an allogeneic bone marow transplant,
irradiation, and an LCMV infection. This was true irrespective of whether mice were
additionally treated with anti-CD154 mAb (Group 5 , 20% survival, N=5) or not (Group
, 0% survival, N=15). Combined, these data suggest that mouse mortality is dependent
on the combination of three treatments: 6 Gy of irradiation, a day 0 LCMV infection and
an allogeneic bone marow transplant.
Table 5. Survival of C57BL/6 mice treated with various conditioning regimens
JH__-
Group LCMV Anti-CD154 mAb Allogeneic Survival
Bone Marrow
at weeks
100%
Yes 100%
Yes 89%
68%Yes Yes
,,7
Yes Yes 20%
Yes Yes Yes
Legend to Table 5: C57BL/6 mice were treated with 6 Gy of irradiation. When
indicated, recipients were also treated with one or more of the following: two 0.5 mg
injections of anti-CD154 mAb given on day 0 and day +3, LCMV infection on day 0, or
injection with 25 million BALB/c allogeneic bone marow cells. Mice were observed
during a 4-week period following the initiation of the varous treatments.
H..
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2. LCMV infection prevents allogeneic bone marrow engraftment via an allogeneic-
specific response
We next sought to determne whether the presence of allogeneic bone marow 
our LCMV -infected recipients invoked a non-specific destruction of injected bone
marow cells or whether they induced a specific anti-allogeneic response. In order to
distinguish between these two possibilities, irradiated recipients were injected with
syngeneic and allogeneic bone marow simultaneously and than infected with LCMV.
The results are shown in Table 6. Once again, allogeneic bone marow engrafted into the
majority of uninfected irradiated recipients (9/14) and mice survived (14/14), whereas
mice infected with LCMV failed to become chimeric (0/14) and died (0/14). Only 5 of
the 13 uninfected mice (38%) that received both 25 million syngeneic bone marow cells
and 25 millon allogeneic cells had allogeneic engraftment, whereas syngeneic bone
marow engraftment occurred in all 13 mice (100%). Similar results have been reported
previously, as several groups have demonstrated that injection of up to a 10: 1 ratio of
allogeneic to syngeneic bone marow is required to engraft allogeneic cells when co-
injected with syngeneic cells (252 253).
Interestingly, when conditioned recipients of both allogeneic and syngeneic cells
were infected with LCMV on the day of transplantation there was a complete lack of
allogeneic engraftment. Of 17 LCMV -infected recipients of syngeneic and allogeneic
bone marow, 2 mice died before being tested for chimerism. None of the remaining mice
had detectable levels of allogeneic donor cells (0/15), whereas all of these mice contained
high levels of syngeneic cells (15/15). Moreover, 14 of the 17 (82%) total mice survived
suggesting that syngeneic engraftment saved these mice from death. Overall, these data
suggest that allogeneic bone marrow, in LCMV-infected recipients treated with anti-
CD154 mAb and sublethal irradiation, invokes a specific anti-allogeneic response.
Further they also suggest that syngeneic bone marow engraftment can prevent death in
mice treated with 6 Gy, anti-CDl54 mAb and given an LCMV infection at the time of
allogeneic bone marow transplantation.
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Legend to Table 6: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of either 25 x 
allogeneic cells , or 25 x 10 allogeneic plus 25 x 10 syngeneic bone marow cells. Anti-
CD154 mAb (0.5 mg) was injected intraperitoneally into all mice on the day of
irradiation and on day +3. Mice were injected on day 0, immediately after the bone
marow transplant, with LCMV. The percentage of H2 or Ly5. 1 donor-origin PBMC
was determned by flow cytometry 2-4 weeks after bone marow transplantation.
Chimerism was defined as the presence of :;1 % MHC class donor-origin cells two
weeks after transplantation.
100
3. Lack of allogeneic bone marrow engraftment can be overcome when high
numbers of donor bone marrow cells are injected into LCMV -infected recipients
We next tested whether increasing the injected dose of allogeneic bone marow
cells into our LCMV -infected recipients could overwhelm their resistance to allogeneic
bone marow engraftment. C57BL/6 mice were treated with our usual conditioning
regimen of 6 Gy irradiation and anti-CD154 mAb. These mice were then split into
varous groups and injected with increasing doses of allogeneic BALB/c bone marow
cells ranging from 25 to 200 millon, followed immediately by an LCMV infection. The
results, shown in Table 7, once again document that uninfected recipients injected with
25 million allogeneic bone marow cells readily become chimeric , whereas similarly
treated LCMV-infected mice fail to become chimeric and die. When 50 or 100 million
allogeneic bone marow cells were injected into LCMV -infected mice, there was stil a
complete lack of detectable donor cell engraftment and all mice died. In contrast, 2 of the
3 mice injected with 200 millon allogeneic bone marow cells became chimeric and
survived, suggesting that the failure of allogeneic bone marow to engraft in LCMV-
infected mice can be overcome by increasing the amount of allogeneic bone marow cells
injected.
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Legend to Table 7: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of allogeneic bone
marow ranging from 25 to 200 millon cells. Anti-CD154 mAb (0.5 mg) was injected
intraperitoneally into all mice on the day of irradiation and on day +3. When indicated
mice were infected with LCMV immediately after transplantation. The percentage of H2
donor-origin PBMC was determned by flow cytometry 5 weeks after bone marow
transplantation. Chimerism was defined as the presence of :;1 % MHC class r donor-
origin cells two weeks after transplantation.
103
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4. The bone marrow and lymphoid compartments in LCMV -infected recipients
given irradiation, anti-CDl54 mAb, and allogeneic bone marrow are markedly
hypoplastic
To determne the cause of death in allogeneic bone marrow recipients infected
with LCMV on the day of bone marrow transplantation, cohorts of control and infected
bone marow recipients were killed 7 or 14 days after transplantation. Light microscopic
analysis of sections of femurs of infected mice (N=8) revealed severe reductions in the
number of all hematopoietic populations (Figure 8). Reductions in marow cellularty
averaged 86:!12% (range 60-97%) compared to un infected controls. Histological
examnation of the spleens of LCMV -infected mice revealed lymphoid depletion in all
cases, and, with the exception of a single splenic nodule in one mouse that showed
regenerative activity, there was no evidence of extramedullary hematopoiesis.
In additional studies total cell counts were performed on both spleen and femoral
bone marow recovered 4 to 35 days after transplantation as shown in Figure 9. Femoral
and splenic cell counts were severely depressed immediately after irradiation and
transplantation for syngeneic chimeras, irrespective of whether recipients were infected
with LCMV at the time of transplantation. In both uninfected and infected synchimeric
femurs , cell counts were similar to untreated age-matched control mice 10 days after
transplantation. Splenic cell counts in uninfected syngeneic chimeras returned to
untreated control levels 2 weeks after transplantation, but remained severely depressed 7
weeks after transplantation in LCMV -infected synchimeras.
104
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Uninfected allogeneic chimeras also had depressed femoral and splenic cell
counts immediately after transplantation. As was the case with synchimeric mice,
recovery was much faster in the bone marow comparment than in the spleen. Femoral
cellularty was back to control levels 2 weeks after transplantation, whereas spleen
cellularty was stil depressed 7 weeks after transplantation. In contrast to all other
groups , however, cell counts in the recipients of allogeneic bone marow infected with
LCMV on the day of transplantation never recovered, and all mice died before day 21.
Splenic and femoral cell counts in these mice were approximately 1 millon cells at all
time points tested, compared to the 100 millon spleen cells and 25 millon femoral cells
found in age-matched untreated wild type C57BL/6 mice. This cellularty data combined
with the histological analyses suggest that recipients given an allogeneic bone marow
transplant, our conditioning regimen of 6 Gy and anti-CDl54 mAb, and an LCMV
infection at the time of transplantation die as a result of a marked hypoplasia in both the
spleen and bone marow.
I;l
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Figure 8. Histology of femoral bone marrow
,fl
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Legend to Figure 8: Sections of bone marow from C57BL/6 wild type recipients
on day fourteen after injection of (A) Ly5 con genic bone marow, (B) Ly5 congenic bone
marow and LCMV, (C) allogeneic BALB/c bone marow, or (D) allogeneic BALB/c
bone marow plus LCMV. Panel E shows bone marow from a C57BL/6 IF-al3-
receptor knock out mouse and panel F shows bone marow from a LCMV-infected
C57BL/6 IF-al3 receptor knock out mouse on day 13 after bone marow injection. All
mice were given 6 Gy radiation and two doses of anti-CDl54 mAb on day 0 and 
relative to bone marrow cell injection on day O. LCMV was given on day O. The marrow
from the mouse that received allogeneic BALB/c bone marow (D) shows severe marow
hypoplasia. The other marows are unremarkable. (Hematoxylin and Eosin, magnification
=131).
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Figure 9. Cell counts in the femoral and splenic compartments of uninfected and
LCMV -infected recipients of allogeneic or syngeneic bone marrow
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Legend to Figure 9: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours of
irradiation all recipients received a single intravenous injection of 25 x 10 donor bone
marow cells. Anti-CD154 mAb (0.5 mg) was injected intraperitoneally on the day of
irradiation and on day +3. LCMV was given on the day of transplantation to mice as
indicated. At the varous time points , femora from the right leg and spleens were removed
from mice and prepared for cell counts as described in Methods. Cell counts are shown as
the mean :t 1 s.d. The dotted horizontal lines indicate the mean splenic and femoral bone
marow cell numbers in 3 untreated 12-week-old C57BL/6 mice.
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5. Host IFN -al3 receptor expression is required for LCMV -induced hypoplasia and
death in allogeneic bone marrow recipients given anti-CDl54 mAb
Having discovered severe hypoplasia restrcted to recipients of allogeneic bone
marow and LCMV infection, we next sought to determne its cause. We first
hypothesized that the cause was related to cytokine release. Reversible depression of
hematopoiesis is known to occur early in the course of LCMV infection and has been
reported to be a direct effect of lF-al3 (251). To determne the role of IF-al3 in our
model system, we repeated our experiments using 129/Sv IF-al3 receptor (IF-aI3R)
knockout mice (216). 129/Sv+/+ and 129/Sv IF-aI3R knockout mice were irradiated (6
Gy), given 25 million BALB/c bone marow cells and two injections of anti-CD 154 mAb
on days 0 and +3. Half of the mice were also infected with LCMV on the day of
transplantation. As shown in Table 8, uninfected 129/Sv+/+ and 129/Sv IF-aI3R
knockout recipients readily accepted BALB/c bone marow and became chimeric. As
expected, LCMV -infection of control 129/Sv +/+ recipients led to failure of engraftment
and death. Therefore, the ability of LCMV to induce death in recipients treated with 6 Gy
of irradiation, anti-CD154 mAb and infected with LCMV on the day of transplantation is
not strain-specific as two different mice strains (C57BL/6 and 129/Sv) died shortly after
receiving this conditioning regimen.
In contrast to the 129/Sv+/+ recipients, LCMV infection of 129/Sv IF-aI3R
knockout recipients also led to failure of the bone marow allograft, but all of the mice
survived. As was the case for LCMV -infected C57BL/6 recipient mice (Figure 8),
histological study of LCMV-infected SV129+/+ recipients revealed bone marow
110
...
hypoplasia and splenic lymphopenia. In contrast, the spleen and bone marow of SVl29
IFN-aI3R knockout mice treated in a similar way showed normal cellularty 14 days after
transplantation (Figure 8). These data suggest that LCMV -induced death was the
consequence of a Type 1 interferon-mediated process, but rejection of the allogeneic
marow graft was due to a different mechanism.
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Legend to Table 8: Groups of 129/Sv wild type and 129/Sv IFN-al3 receptor
knockout mice were treated with irradiation, 25 million BALB/c bone marow cells and
anti-CDl54 mAb. Imediately after transplantation, mice in each of these two groups
were randomized, and half of each group was injected with LCMV. The percentage of
donor-origin PBMC was determned by flow cytometry at varous time points after
transplantation. Each data point represents the mean:: I s.d. *Thirteen mice in this cohort
died before they could be tested for chimerism.
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6. Circulating levels of IFN-al3 are similar in LCMV -infected recipients of syngeneic
i"' and allogeneic bone marrow
After discovering that host IF-al3 receptor expression is critical for the mortality
.-!
of mice that received allogeneic bone marow , irradiation, and an LCMV infection, we
hypothesized that these mice would have higher circulating levels of IF- al3 than
similarly treated mice that received syngeneic bone marow. In order to test this
hypothesis, C57BL/6 mice were treated with irradiation and anti-CDl54 mAb 
previously described. Recipient mice were then split into two groups. The first group
received an allogeneic bone marow transplant, while the second group received a
syngeneic bone marrow transplant. Following the bone man-ow transplant both groups
were immediately infected with LCMV. At selected time points (2, 4 and 14 days post-
transplantation) mice were tested for levels of circulating IF-al3 in serum. As seen in
Table 9 , there were no significant differences in the circulating levels of IF-al3 between
LCMV -infected recipients of allogeneic or syngeneic bone marow at all 3 time points
tested. Early after infection, high levels of IFN-al3 were detected in both syngeneic and
allogeneic recipients. As expected, levels of circulating IF-al3 dropped dramatically by
day 14 post-infection.
There are several possible explanations for our inability to find a difference in the
circulating levels of IF-al3 between LCMV-infected recipients - of syngeneic or
allogeneic bone marow. One possibilty is that increased levels of IF-al3 in LCMV-
infected allogeneic bone marow recipients are only found at the site of its damage, the
..,
:\1
114
bone marow. A second possibility is that LCMV-induced IF-al3 interacts with other
cytokines such as IF-y or TNF-a. Both of these cytokines can inhibit hematopoietic
progenitor cell growth (254), and therefore could combine with LCMV-induced IF-al3
to produce recipient death.
In a preliminary experiment, we pretreated C57BL/6 mice with anti-IFN-y mAb
before giving them our normal conditioning regimen of sublethal irradiation, anti-CD154
mAb, and an allogeneic bone marow transplant. All of the uninfected C57BL/6 mice
treated with anti-IF-y mAb survived (5/5) and became chimeric (5/5 , average of 79%
donor-origin cells in PBMC). Similarly, 4 of 5 LCMV-infected mice treated with anti-
IF-y mAb survived, but none of the 4 surviving mice became chimeric. This suggests
that IF-y may be involved, along with IF-al3, in the death of mice that receive
allogeneic bone marow, sublethal irradiation, anti-CDl54 mAb and a day 0 LCMV
infection. Unfortunately, the role of TNF-a has yet to be determned in our system.
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Legend to Table 9. C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of 25 x 10 syngeneic
(C57BL/6-Ly5. 1) or allogeneic (BALB/c) bone marow cells. Anti-CD154 mAb (0.5 mg)
was injected intraperitoneally on the day of irradiation and on day +3. LCMV was given
on day 0, the day of transplantation. On the day indicated, NCTC-929 cells were
incubated in 96-well plates with 2-fold dilutions of peripheral blood overnght. These
mixtures were than infected with VSV, incubated for 3 days and than examined to
determne the last dilution of peripheral blood that prevented VSV -induced cytotoxicity.
Data are presented as Log of the last dilution that prevented cytotoxicity, and as an
estimated units/mL based on infected mixtures of NCTC-929 cells with known quantities
of purified IFN-al3.
' ' ' :': ' .' '
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7. Poly I:C treatment is unable to induce hematopoietic hypoplasia and death but
does prevent allogeneic bone marrow engraftment
We have shown that host IF-al3 receptors playa pivotal role in the mortality of
mice infected with LCMV immediately after receiving both irradiation and an allogeneic
bone marow tra:rsplant. However, we were unable to detect a difference in the levels of
circulating IF-al3 between LCMV -infected recipients of syngeneic bone marow (which
become chimeric and survive) and allogeneic bone marow (which fail to become
chimeric and die). In order to further our understanding of the role of IF-al3, we tested
whether a Poly I:C injection, a potent inducer of type I interferons in mice, could
simulate an LCMV infection and produce mortality in irradiated recipients of allogeneic
bone marow.
Groups of C57BL/6 mice were treated with 6 Gy of irradiation , anti-CD154 mAb
and given a BALB/c allogeneic bone marrow transplant. Mice were than randomized into
three separate groups. The first group received no furter treatment. The second group
received a Poly I:C injection of 0.5 mg immediately after transplantation and the third
group received two 0.5 mg injections of Poly I:C on the day of transplantation and 5 days
later.
Surprisingly, as shown in Table 10, Poly I:C treatment did not result in the death
of any of the recipient mice. This was true for mice given either 1 or 2 injections of Poly
I:C. Interestingly, although Poly I:C treatment did not prevent death, it did prevent the
engraftment of allogeneic bone marow, implying that a Poly I:C-induced response
(either cytokines or a cellular component) is capable of preventing the engraftment of
, -
: r.
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allogeneic bone marow in recipients treated with sublethal irradiation and anti-CDl54
mAb.
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Legend to Table 10: C57BL/6 mice were irradiated with 6 Gy. Within 1-3 hours
of irradiation all recipients received a single intravenous injection of 25 x 10 allogeneic
(BALB/c) bone marow cells. Anti-CD154 mAb (0.5 mg) was injected intraperitoneally
on the day of irradiation and on day +3. Group 1 received no further treatment. Group 2
was given an intravenous injection of Poly I:C (0.5 mg) on the day of transplantation.
Group 3 was treated with two 0.5 mg injections of Poly I:C, on day 0 and day +5. The
percent chimerism was determned by flow cytometry analyses of peripheral blood taken
2 weeks post-transplantation.
, .
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8. NK cells are not involved in preventing allogeneic bone marrow engraftment in
LCMV -infected recipients
Although the removal of host IF-al3 receptors prevented death in LCMV-
infected allogeneic bone marow recipients treated with sublethal irradiation and anti-
CDl54 mAb , the injected allogeneic cells stil did not engraft. Therefore, the survival of
these mice depended on the recovery of the host marow . We next questioned whether
failure of allogeneic bone maITOW engraftment in the presence of LCMV infection was
the result of cell-mediated immune rejection.
To identify the cell type responsible for graft failure we conducted a series of cell
depletion studies focused on NK cells and T cell subsets. NK cells were of paricular
interest because they reportedly playa pivotal role in the rejection of murine allogeneic
bone marow transplants (232 255 256). Furthermore, we have shown that Poly I:C
injection at the time of transplantation prevents the engraftment of allogeneic bone
marow into irradiated recipients , and Poly I:C is a potent activator of NK cells (257).
We therefore first tested whether NK cells playa role in the lack of allogeneic
bone marow engraftment in LCMV -infected mice. As shown in the upper half of Table
, pre-transplantation administration of anti-NK1.1 , anti-asialo-GMI or anti-CD122
mAbs had little or no effect on subsequent hematopoietic chimerism or survival in
C57BL/6 recipients of BALB/c bone marow and anti-CD154 mAb in the absence of
LCMV.
The effects of these reagents on survival and chimerism in mice infected with
LCMV on the day of bone marow transplantation are shown in the lower half of Table
122
11. Once again , LCMV infection at the time of transplantation prevented the engraftment
of allogeneic bone marow and caused mice to die. Pre-transplantation administration of
anti-NK1.I mAb slightly improved the survival of these LCMV-infected mice (29%
survival vs. 6% survival in - untreated LCMV -infected controls), but, allogeneic bone
marow failed to engraft. In mice pre-treated with anti-CDI22 mAb the majority of mice
survived (7 of 9 mice, 78% survival), but again, allogeneic bone marow engraftment
failed to occur. Treatment of mice with anti-asialo-GMI mAb, however, prevented
LCMV -induced death and allowed allogeneic bone marow engraftment. In their
aggregate, these results suggest that NK cells are not responsible for preventing
allogeneic bone marow engraftment in LCMV-infected recipients of anti-CDI54 mAb
and irradiation.
Asialo-GMI is expressed on the majority of NK cells in C57BL/6 mice, but is
also expressed on activated T cells including those that express CD4, CD8 , TCR-al3 and
TCR-yo (258). We therefore next focused on these 4 T cell subsets to determne what cell
type was responsible for preventing the engraftment of allogeneic bone marow 
LCMV- infected mice.
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Legend to Table 11: C57BL/6 mice were randomized into four groups. The first
received no treatment. The remaining groups were treated with injections of the listed
depleting reagents. Treatments were begun on days -8 to -I before transplantation and
completed by day +6 as described in Methods. On day 0 all mice received 6 Gy of
radiation, 25 millon BALB/c bone marow cells and the first of 2 doses of anti-CDI54.
Mice in all four treatment groups were then randomized a second time, and half received
LCMV immediately after bone marow transplantation. The remaining half received no
virus. The percentage of donor-origin PBMC was determined by flow cytometry 2 and 4-
6 weeks after transplantation as described in Methods. Each data point represents the
mean:t 1 s.d. *Some mice did not survive to the two week time point, the first time point
at which the extent of chimerism was quantified in this experiment. a: p=N.S. vs.
untreated LCMV-infected controls; b: po:O.OOl vs. untreated LCMV-infected controls
(Fisher exact statistic).
Jf'
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9. A population of CD8+TCRal3+asialo-GMl+ cells prevents allogeneic bone marrow
engraftment in LCMV -infected recipients treated with 6 Gy and anti-CDl54 mAb
Although the depletion of NK cells appears to have a positive effect on the
survival of LCMV -infected mice, it did not enhance the engraftment of allogeneic bone
marow. Therefore, we next focused our experiments on T cell subsets. Recipient mice
were either wild type C57BL/6 mice or C57BL/6 mice in which the CD4 , CD8 , TCR-al3
or TCR-y8 lymphocyte surface antigen gene was disrupted by homologous
recombination. All mice were treated with our usual conditioning regimen of 6 Gy
irradiation, 25 millon BALB/c allogeneic bone marow cells and anti-CDl54 mAb.
As shown in the upper half of Table 12 , the absence of CD4, CD8 , TCR-al3, or
TCR-y8 cells had little or no effect on the generation of hematopoietic chimerism or
survival of C57BL/6 knockout recipients of BALB/c bone marow and anti-CD154 mAb
in the absence of LCMV infection.
In contrast to LCMV -infected wild-type control mice, which failed to develop
allogeneic hematopoietic chimerism and died, allogeneic bone marow transplantation
into either LCMV-infected CD8 or TCR-al3 knockout mice resulted in greatly enhanced
survival and robust hematopoietic chimerism. LCMV -infected CD8 knockout mice
became chimeric in 100% of the mice tested (N=9), with a survival rate of 90% (N=lO).
Likewise, LCMV-infected TCR-al3 knockout mice had a high rate of both chimerism
(89%, N=9) and survival (89%, N=9). Transplantation into LCMV -infected CD4 or
TCR-yo knockout mice resulted in slightly improved survival, but no engraftment of
126
donor bone marow was detected. Together, these data strongly imply that a population
of CD8+TCR-al3+asialo-GMl+ T cells prevents allogeneic bone marrow engraftment in
LCMV-infected recipients treated with irradiation and anti-CDl54 mAb.
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Legend to Table 12: Groups of C57BL/6 wild type and C57BL/6 CD4, CD8,
TCR-al3 or TCR-y8 knockout mice were treated with 6 Gy of irradiation, 25 millon
BALB/c bone marrow cells and anti-CDl54 mAb according to our standard
transplantation protocol as described in Methods. Imediately after transplantation, mice
in each of the five groups were randomized, and half of each group was injected with
LCMV on the day of transplantation. The percentage of donor-origin PBMC was
determned by flow cytometry 2-4 and 7 weeks after transplantation as described in
Methods. Each data point represents the mean:t I s.d. *Some mice did not survive to the
two week time point, the first time point at which the extent of chimerism was quantified
in this experiment. a: p=N.S. vs. untreated control; b: poeO.OOl vs. untreated control
(Fisher exact statistic).
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10. The prevention of allogeneic bone marrow engraftment does not require the
Fas/FasL pathway or perforin
After discovering that CD8+TCR -al3+ asialo-GM 1 + T cells are involved in the
rejection of allogeneic bone marow in mice treated with sublethal irradiation, anti-
CD154 mAb , and an LCMV infection on the day of transplantation, we next sought to
determne the mechanism responsible. T cells can destroy allogeneic bone marow cells
through several mechanisms , including the release of perforin
, granzyme, or TNF-a, as
well as by activating the Fas-FasL pathway (44,45).
To help determne which of these mechanisms may be involved, we performed
allogeneic bone marow transplants into Faslpr/ Faslp\ FasLgld/ FasLgld and pfp/pfp
(perforin) C57BL/6 knockout mice. As shown in Table 13 , the absence of Fas, FasL or
perforin did not alter the engraftment of allogeneic bone marow or the survival of
uninfected mice. When these mice were infected with LCMV on the day of
transplantation, all four groups contained undetectable levels of donor cell engraftment.
Furthermore, the vast majority of these mice died 2-3 weeks after transplantation. These
results suggest that neither the Fas/FasL pathway nor the release of perforin are required
for the prevention of allogeneic bone marow engraftment in recipient mice treated with
sublethal irradiation, anti-CD 154 mAb, and given an LCMV infection on the day of
transplantation. Further experiments wil be necessary in order to determne whether the
release of granzymes or TNF-a are required for the rejection of allogeneic bone marow
in mice treated with sublethal irradiation , anti-CD 154 mAb, and an LCMV infection on
the day of transplantation.
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Legend to Table 13: Groups of C57BL/6 wild type and Faslpr/ Fas lpr, FasLgld
FasLg1d and pfp/pfp C57BL/6 knockout mice were treated with 6 Gy of irradiation, 25
millon BALB/c bone marow cells and anti-CD154 mAb according to our standard
transplantation protocol as described in Methods. Imediately after transplantation , mice
in each of the four groups were randomized, and half of each group was injected with
LCMV on the day of transplantation. The percentage of donor-origin PBMC was
determned by flow cytometry 8 weeks after transplantation as described in Methods.
Each data point represents the mean :t 1 s.
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11. Chapter III Summary
Allogeneic bone marow engraftment successfully occurs in C57BL/6 mice using
a combination of sublethal irradiation and anti-CDl54 mAb treatment. However, LCMV
infection at the time of transplantation prevents the engraftment of bone marrow and
causes death 2-3 weeks after transplantation. The death of thes, mice was associated with
a severe hypoplasia in both spleen and femurs of LCMV-infected mice. Furthermore
death was dependent on the combined treatment of 6 Gy irradiation, LCMV infection at
the time of transplantation, and an allogeneic bone marow transplant.
The prevention of bone marow engraftment and the induction of mouse mortality
appear to be due to two distinct and separate mechanisms. Mortalty requires the presence
of host IF-al3 receptor expression and rejection of allogeneic bone is due to a
population of CD8+ T cells that express both TCR-al3 and asialo-GMI.
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DISCUSSION
Currently, the transplantation of human hematopoietic stem cells relies on the
combination of lethal conditioning and immunosuppression. The use of lethal
conditioning leads to severe neutropenia, which results in a varety of bacterial, fungal
and viral infections (163). Moreover, these infections have been implicated in allograft
rejection, the enhancement of GVHD, and the loss of graft function (6 228-230).
In attempts to overcome these obstacles, a new wave of protocols for stem cell
transplantation have focused on the induction of hematopoietic chimerism using sublethal
irradiation. By reducing the toxicity involved, these protocols hope to substantially
reduce the extent and duration of neutropenia and immune suppression associated with
stem cell transplantation. Furthermore, the use of sublethal conditioning could make stem
cell transplantation a realistic option for non-lethal malignancies , autoimmune diseases
and organ transplantation.
The use of co stimulation blockade in combination with sublethal irradiation is one
approach that has been used to induce hematopoietic chimerism. Costimulation blockade
of T cell activation has been found to induce potent donor-specific non-responsiveness.
Furthermore, co stimulation blockade can facilitate the establishment of allogeneic
hematopoietic chimerism, while also significantly reducing the toxicity of the
conditioning regimen (4 181 184 185 259).
Despite the promise inherent in stem cell transplantation protocols based on
costimulation blockade, significant issues of safety and durability remain to be assessed.
In paricular, patients treated with partial myeloablation combined with costimulation
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blockade could be less resistant to viral infection and its associated pathophysiological
effects. Furthermore, the abilty of viruses to induce inflamatory cytokines, T cell
growth and differentiation factors and virus-specific CTL that react to allogeneic targets
could potentially compromise graft survival and overcome tolerance (5 260,261). Finally,
many viruses can enhance GVHD after bone marow transplantation (6 262).
To begin to investigate these issues, we have set up a model of allogeneic bone
marow transplantation based on sublethal conditioning and costimulation blockade that
allows stable and long-term engraftment of allogeneic bone marow in the absence of
GVHD. We then used this model to test both the safety and effcacy of bone marow
transplantation based on costimulation blockade and sublethal conditioning by infecting
mice with LCMV either at the time of tolerance induction or at selected time points after
transplantation.
Using 6 Gy of irradiation , two doses of anti-CD 154 mAb , and 25 millon BALB/c
bone marow cells, hematopoietic chimerism was established in the majority of C57BL/6
recipient mice. Chimeric mice demonstrated long-term and stable mixed hematopoietic
chimerism for up to one year after transplantation. Furthermore, the peripheral blood
from chimeric mice contained high levels of donor-derived B and T cells
monocytes/macrophages and granulocytes, indicating that hematopoietic chimerism in
these mice was multi-lineage.
To determne whether the conditioning regimen induced donor-specific tolerance,
conditioned recipients were transplanted with both donor-origin and third pary skin
grafts. Skin grafts were used because they are considered one of the most strngent tests
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for tolerance induction. All chimelic mice permanently accepted donor-specific BALB/c
(H2 ) skin grafts while readily rejecting third pary CBA/JCr (H2 ) skin grafts
demonstrating that T cell function was present and that mice were specifically tolerant to
-expressing cells.
A major complication in allogeneic hematopoietic chimeras is GVHD. In order to
test for the presence of GVHD in our chimeric mice we performed histological analyses
on small and large intestine, liver, lung and skin. None of these samples showed immune
cell infitration suggestive of GVHD.
Hematopoietic chimerism could be established in C57BL/6 mice using as little as
5 Gy of irradiation (Table I). However, only the combination of 6 Gy of irradiation or
more in combination with anti-CD 154 mAb consistently induced hematopoietic
chimerism in the majority of recipient mice. Interestingly, anti-CDl54 mAb was required
for hematopoietic chimerism at 6 Gy, but not at 7 Gy. Although mice became chimeric at
7 Gy without anti-CDl54 mAb, chimerism was transient and disappeared within 7 weeks
of transplantation. Because our goal was to establish stable chimerism while reducing the
toxicity of the host conditioning, the combination of 6 Gy irradiation and anti-CDl54
mAb was used in all subsequent experiments.
The abilty of anti-CDl54 mAb to induce chimerism at 6 Gy suggests that anti-
CD154 mAb lowers the required dose of irradiation necessary for successful bone
marow engraftment. Previous experiments transplanting C57BL/6 bone marow into
BALB/c recipients supports this concept. C57BL/6 bone marow engrafted into BALB/c
recipients treated with 5 Gy regardless of whether they received anti-CDl54 mAb (190).
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However, BALB/c recipients treated with only 4 Gy of irradiation required anti-CDl54
mAb for engraftment. Therefore, in both C57BL/6 and BALB/c recipients, anti-CDl54
mAb reduced the amount of irradiation necessary for hematopoietic chimerism by - 1 Gy.
Besides lowering the required dose of irradiation, the addition of anti-CDl54
mAb has been implicated in the prevention of HVGD and GVHD. In a model of GVHD
initiated by the injection of parental bone marow into Fl recipient mice, the addition of
anti-CDl54 mAb prevented the induction of both acute and chronic forms of GVHD
(263). Our laboratory has extended these observations by documenting that anti-CDl54
mAb prevented both GVHD and HVGD in BALB/c hematopoietic chimeras created with
a sublethal conditioning protocol (190). The experiments performed in this thesis confirm
these results, as chimeric C57BL/6 mice that received 6 Gy of irradiation and anti-CDl54
mAb showed no overt or histological evidence of GVHD.
It appears that there is an interplay between the amount of anti-CDl54 mAb
injected, the number of anti-CDl54 mAb injections , the number of injected bone marow
cells, and the amount of inadiation that is necessar for successful engraftment of
allogeneic bone marow. Several laboratories have shown that increasing the amount of
anti-CDl54 mAb injections or increasing the amount of injected bone marow cells
lowers the minimum amount of irradiation necessary for allogeneic bone marow
engraftment (179, 182 184). These results suggest that the amount and duration of anti-
CDl54 mAb , the level of irradiation and the number of injected allogeneic bone marow
cells can all interfere with the competition between donor and host hematopoietic stem
cells in regard to their growth and expansion in the recipient.
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Using our standard protocol of 25 millon allogeneic bone marow cells, 2
injections of anti-CDl54 mAb and 6 Gy of irradiation, we observed three different
outcomes. The majority of treated mice became chimeric and remained chimeric
throughout the length of our studies. However, some mice failed to become chimeric
while other mice lost their chimerism shortly after transplantation. The latter tended to be
mice with low initial engraftment that eventually disappeared. The loss of chimerism in
these mice is most likely I) the result of the few donor-derived cells that engraft being
outcompeted by host marow cells, or 2) the engraftment of progenitors and not true stem
cells that accounted for the transient chimerism observed.
A low percentage of treated mice in our experiments never became chimeric. One
explanation for the lack of chimerism in our experimental mice is the anti-CDl54 mAb.
Our laboratory is continuously generating new lots of purified antibody from ascites.
Although quality control of each lot for concentration and endotoxin is performed, and
the same lot of anti-CD 154 mAb is always used within a single experiment, multiple lots
of antibody have been used over the course of these experiments. Hence, any varabilty
in the biological activity of anti-CD 154 mAb may reflect subtle changes in the number of
mice that become chimeric or in the level of donor cell engraftment that occurs. In
support of this possibilty, the majority of mice that failed to become chimeric were not
dispersed evenly throughout the experiments, but rather were concentrated in just a few
of the experiments performed. Unfortunately, the lots of anti-CD154 mAb used where
mice failed to become chimeric were not available for retrospective analyses of purity or
potency.
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These data document a model system characterized by mixed hematopoietic
chimerism and donor-specific transplantation tolerance in the absence of GVHD and
minimal preparative risk to the recipient. Because the system accurately models an
approach that could well be put into clinical practice, it was deemed appropriate for use
in analyses of safety and durability in the presence of viral infection, which is a common
complication of clinical bone marow transplantation. We addressed the issue of safety
by studying the effects of viral infection on mice undergoing treatment to induce
hematopoietic chimerism. We also addressed issues of both safety and durability by
examning the effect of delayed exposure to virus on mice in which mixed chimerism had
been successfully established IS or SO days earlier.
The results of these studies were extremely surprising, as essentially all mice
given an allogeneic bone marow transplant and infected with LCMV on the day of
transplantation died 2-3 weeks after transplantation. This is in stark contrast to uninfected
controls , where only a few widely scattered deaths occurred.
Typically, an intraperitoneal injection of LCMV-Arstrong presents as a non-
cytopathic infection that is cleared within two weeks (197). However, in mice treated
with a sublethal dose of 6 Gy irradiation (10- 11 Gy is lethal for CS7BL/6 mice), injected
with an allogeneic bone marow transplant, and infected with LCMV at the time of
transplantation, a lethal outcome was observed. This lethal outcome was not observed in
mice that received syngeneic bone marow and infected with LCMV on the day of
transplantation.
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In contrast, both syngeneic and allogeneic chimeras infected with LCMV 2 or 7
weeks after transplantation survived. The survival of mice that received a delayed LCMV
infection suggests that LCMV causes the death of bone marow transplant recipients only
when infection occurs during the immediate period of allogeneic bone marow
transplantation. Further, it suggests that LCMV infection does not interfere with the
maintenance of hematopoietic chimerism, indicating that once chimerism and tolerance
are established they are unaffected by viral infection.
The differential survival of acutely infected syngeneic vs. allogeneic bone marow
recipients was not due to the differential ability of these mice to clear LCMV, as both
syngeneic and allogeneic bone marow recipients infected with LCMV on the day 
transplantation were unable to clear the viral infection. The inability of these mice to
clear a day 0 LCMV infection was not due to anti-CD 154 mAb induced co stimulation
blockade, as LCMV -infected CD 154 knockout mice generate a strong LCMV -specific
CTL response that clears the LCMV infection (264). The persistence of virus in day 0
LCMV -infected mice is likely due to radiation-induced elimination of peripheral T cells
as treatment with 6 Gy induces a 50% decrease in splenic and femoral cell counts.
When LCMV infection was given 15 days after transplantation, allochimeric mice
were stil unable to clear the infection, whereas synchimeras successfully cleared the
virus. Allochimeric mice were only able to clear the LCMV infection when it occurred 50
days after transplantation. As LCMV infection is cleared by LCMV -specific CD8+ CTL
(215), it is likely that synchimeras recover the ability to produce this population of cells
quicker than allochimeras. This reasoning is supported by our cellularty studies. Splenic
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and femoral cell numbers in syngeneIc chimeras returned to levels comparable to
untreated control mice within 14 days of irradiation and transplantation (Figure 6). In
contrast, the splenic cellularty of allogeneic chimeras took 7 weeks to recover 80% of
the cell counts of untreated mice.
After documenting that LCMV infection abrogated the induction of hematopoietic
chimerism but not the maintenance of chimerism, we next asked whether LCMV
infection could interfere with either the induction or maintenance of donor-specific
tolerance. We were unable to test the effect of LCMV infection on the induction of
donor-specific tolerance in allogeneic chimeras as these recipients died soon after
transplantation. In order to determne whether LCMV infection altered the maintenance
of donor-specific tolerance, syngeneic and allogeneic chimeras that were stably chimeric
were infected with LCMV immediately after being transplanted with donor-origin skin
grafts. In both syngeneic and allogeneic recipients, LCMV infection at the time of skin
grafting did not cause graft rejection suggesting that LCMV infection does not alter the
maintenance of donor-specific tolerance.
In contrast to the findings presented here with LCMV-infected bone marow
transplant recipients, our laboratory has previously shown that LCMV-infection can
abrogate the induction and maintenance of tolerance using a two-element protocol of
DST and anti-CDlS4 mAb (238). In those experiments , LCMV infection enhanced the
rejection of skin allografts, even when infection occurred 29 days after skin grafting.
Only when LCMV infection occurred SI-S7 days after skin grafting did LCMV -infected
mice display similar graft survival to uninfected controls. These experiments suggest that
.. 
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LCMV infection interfered with both the initiation and maintenance of donor-specific
peripheral tolerance using a two-element protocol of DST and anti-CD154 mAb. In
contrast, LCMV infection abrogated the induction of central donor-specific tolerance but
did not alter the maintenance of central transplantation tolerance using allogeneic bone
marow , 6 Gy of irradiation, and anti-CD154 mAb.
The last goal of this thesis was to determne 1) the mechanism of LCMV-induced
. mortality in recipients of allogeneic bone marow and a day 0 LCMV infection, and 2)
the mechanism of LCMV-induced abrogation of allogeneic bone marow engraftment.
Initially, we hypothesized that mortality was simply due to the lack of allogeneic
bone marow engraftment. This hypothesis would suggest that mice that receive
irradiation, an acute LCMV infection, and anti-CDl54 mAb treatment without receiving
a bone marow transplant would succumb to aplasia and death. Although 30% of the
mice treated in this way died, the rate of death increased to 95% when an allogeneic
bone marow transplant was added to the conditioning regimen. When anti-CDl54 mAb
was removed from this conditioning regimen, approximately 20% of the mice stil died
suggesting that anti-CDl54 mAb is not involved in the death of these recipients.
Therefore, the combination of allogeneic bone marow , 6 Gy of irradiation and an LCMV
infection at the time of transplantation is suffcient to induce death.
To analyze why acutely infected allogeneic bone marow recipients were dying,
we performed histological and cellularty analyses at varous time points after
transplantation. Spleen and bone marow cell counts were drastically reduced in acutely
infected allogeneic bone marow recipients compared to similarly treated LCMV-infected
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syngeneIc bone marrow recipients. The reduction in marow cellularty averaged
86:t12% , with a range of 60-97% , leading us to conclude that mice were dying from
severe hematopoietic aplasia.
In the early 1970s a link between LCMV infection and hematopoietic aplasia was
reported (265 266 266,267). In those experiments, LCMV-infected mice displayed, severe
decreases in both bone marow and splenic cellularty, but this aplasia was only
temporary and did not result in mortality. Ten days post-infection , splenic cell numbers
returned to normal. In contrast, femoral cell counts remained depressed for up to three
weeks after infection. The onset of hematopoietic aplasia was correlated with an increase
in circulating IFN-y and activated NK cells, indicating their possible role in LCMV-
induced hematopoietic suppression.
Recently, it was discovered that LCMV infection of IF-al3 receptor knockout
mice (IF-al3 
DID did not produce the typical hematopoietic stem cell depression seen
in wild type control mice (251). This observation was unique to IF-al3 DID mice, as
LCMV -infection of mice deficient in NK cells, Fas, IF-y, perforin, CD4 or CD8 T cells
allIed to the characteristic decrease in femoral and splenic cell counts (251).
Based on these studies, we tested whether IF-al3 was involved in LCMV-
induced aplasia and death that occurred in acutely infected mice treated with 6 Gy of
irradiation, anti-CD154 mAb, and given an allogeneic bone marow transplant.
Interestingly, all LCMV-infected IF-al3 DID mice that received irradiation and anti-
CD154 mAb survived. Histological examnation of the femurs of LCMV-infected IF-
t!:
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al3 
OJO mice showed normal cellularty 13 days after transplantation, suggesting that
these mice had recovered from the effects of irradiation by this time and that host IFN-al3
receptor expression is involved in LCMV -induced aplasia.
Although LCMV-infected IF-al3 OJO mice survived the conditioning regimen
allogeneic bone marrow was stil unable to engraft into these mice. These results, for the
first time, separated host death from allograft rejection. Therefore, host IF-al3 receptor
expression is necessary for LCMV -induced aplasia and mortality, and a second
mechanism appears to be responsible for the rejection of allogeneic bone marow.
After discovering that host IF-al3 receptor expression is necessary for mortality,
we tested whether circulating levels of IF-al3 vared between LCMV -infected mice that
received syngeneic or allogeneic bone marrow transplants. We hypothesized that
allogeneic recipients that succumbed to LCMV -induced death would contain higher
levels of circulating IF-al3 than their syngeneic counterpars which survived.
Surprisingly, this was not the case. Both syngeneic and allogeneic bone marow
recipients contained high levels of circulating IF-al3 by day 2 post-infection, which
dramatically decreased by day 14. At all time points tested, there was no significant
difference in the circulating IF-al3 levels between LCMV -infected recipients of
syngeneic or allogeneic bone marow.
To further elucidate the role of IF-al3 in our studies, we injected ffce
conditioned with sublethal irradiation and anti-CDl54 mAb with Poly I:C, a known
inducer of type I interferon (268). All mice treated with irradiation, anti-CD154 mAb,
y .
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Poly I:C and then given an allogeneic bone marow transplant survived. This was true for
mice injected with Poly I:C only on the day of transplantation, as well as for mice that
received two injections of Poly I:C (on day 0 and day +5).
Several differences may exist between Poly I:C injection and LCMV infection
that would explain these results. First, the induction of type I interferon that results from
Poly I:C injection is of less intensity and duration compared to the induction of these
cytokines after LCMV infection (Dr. Craig Peacock, personal communications). 
decrease in either the intensity or duration of IF-al3 production could explain why Poly
I:C injected mice survive, whereas LCMV -infected mice die.
A second possibility is that these two treatments result in IF-al3 production at
different sites within treated mice. Both LCMV infection and Poly I:C injection initiate
the production of IF-al3. However, the abilty of LCMV to infect bone marow cells
may also initiate a localized production of IFN-al3, specifically in the bone marow. In
several studies, both in vivo and in vitro IF-al3 has been shown to directly suppress
hematopoiesis (231 269-271). After irradiation-induced damage to the stem cells, this
additional localized production of IF-al3 may initiate the induction of aplasia and
eventual death that is seen in LCMV -infected mice, but not in mice injected with Poly
I:e. Furthermore, this localized production of type I interferon in the bone marow would
not have been detected in our experiments, where only circulating levels of IF-al3 in the
serum were examined.
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A final possibilty is that LCMV infection causes the induction of cytokines or a
cell population that is not induced by Poly I:C infection. In our experiments, the removal
of CD4+ T cells or NK cells did not alter LCMV-induced mortality, suggesting that these
two cell populations are not involved. Two cytokines that may be involved are IF-y and
TNF-a, as both cytokines inhibit hematopoietic progenitor cell growth (254), and
therefore could combine with LCMV-induced IF-al3 to produce recipient death. We
have shown that IF-y is involved in LCMV-induced death, but have not looked to see
whether production of this cytokine vares in LCMV-infection versus Poly I:C injection.
Unfortunately, we have not yet determned whether TNF-a is involved in the abilty of
LCMV infection to cause allograft rejection or recipient death.
The final sets of experiments in this thesis were performed in order to determne
the mechanism of allograft rejection in LCMV -infected mice treated with sublethal
irradiation, anti-CDl54 mAb and given an allogeneic bone marrow transplant. We first
tested whether the rejection of bone marrow cells was specifically directed to allogeneic
targets or whether the response was non-specific. When syngeneic and allogeneic bone
marow were simultaneously injected into uninfected recipients, 5 of 13 mice contained
both allogeneic and syngeneic derived donor cells. In contrast, all 15 LCMV -infected
mice that were injected with both syngeneic and allogeneic man-ow contained syngeneic
donor-derived cells , whereas none of these mice contained allogeneic donor-derived
cells. This result suggests that our conditioning regimen induce a specific anti-allogeneic
response in acutely infected mice treated with sublethal irradiation and anti-CDl54 mAb. '
This allogeneic response was found to be dose-dependant, as the injection of 200 millon
\'"
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allogeneic bone marow cells into LCMV -infected mice treated with irradiation and anti-
CD154 mAb resulted in the engraftment of allogeneic bone marow.
We next focused on the varous cell populations that could be responsible for this
LCMV-induced rejection of allogeneic bone marow. NK cells were of paricular interest
because of their prominent role in the rejection of murine allogeneic bone marow
transplants (232 255 256). Furthermore, we have shown that Poly I:C infection at the
time of transplantation prevents the engraftment of allogeneic bone marow , and Poly I:C
is a potent activator of NK cells (257). Using varous antibodies to deplete NK cells , we
have shown that the absence of NK cells does not prevent the rejection of allogeneic bone
marow associated with a day 0 LCMV infection. Mice depleted with either anti-NK1.1
mAb or anti-CDl22 mAb had undetectable levels of donor cell engraftment.
One interesting observation from these NK cell depletion studies was the results
obtained with anti-CDl22 mAb depletion. In LCMV-infected recipients, CD122
depletion did not permt the engraftment of allogeneic bone marow, but recipient
survival was significantly enhanced. CD122, the interleukin-2 receptor beta chain, is
found on monocytes/macrophages, NK cells, and activated CD8+ T cells (241-243).
Monocytes and macrophages are known to produce IF-al3, and we have shown that
LCMV -infected IF-al3 OtO mice survive an LCMV infection. Therefore, we speculate
that the be eficial effect of anti-CDl22 antibody treatment on the survival of LCMV-
infected allogeneic bone marow recipients is due to the depletion of these IF-al3-
producing myeloid lineage cells.
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As opposed to the other NK cell depleting reagents, depletion of asialo-GMI +
cells prior to transplantation and a day 0 LCMV infection resulted in allogeneic bone
marow engraftment and recipient survival. Asialo-GMI expression in C57BL/6 mice has
been found on NK1.1+ cells , as well as on activated T cells that express TCR-al3, TCR-
yo, CD4 or CD8 (258). As the experiments using anti-CDl22 mAb and anti-NK1.1 mAb
suggest that NK cells are not involved in LCMV -induced allogeneic bone marow
rejection, we next focused on the various populations of activated T cells that express
asialo-GMI.
U sing both depleting antibodies and knockout mice, the critical observation was
that, after infection with LCMV, only three types of recipients survived and became
chimeric: mice depleted of CD8+ T cells, CD8 knockout mice, and TCR-al3 knockout
mice. These data indicate that the mediator of bone marow allograft destrction in
LCMV -infected mice treated with costimulatory blockade is a radioresistant CD8+
NKl. l- asialo-GMl+TCRal3+ T cell.
This conclusion is supported by the finding that anti-CD8 mAb treatment
facilitates the induction of mixed hematopoietic chimerism in sub-lethally irradiated mice
given anti-CD154 mAb plus allogeneic bone marow (180). Furthermore, asialo-
GMI +CD8+ T cells have been implicated as the cause of allograft rejection in mice
treated with the combination of anti-CD154 and CTLA4-Ig (258). These two studies
indicate an important role for alloreactive CD8+ T cells in allogeneic bone marow
rejection. Here, we show that this host alloreactive activity can be greatly amplified by
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VIruS infection to overcome costimulation blockade and prevent allogeneic marow
engraftment.
Similar to the results seen with anti-CD122 mAb, LCMV-infected TCR-
knockout mice showed a marked increase in survival compared to wild-type controls. We
propose that this increased survival is due to the ability of TCR-y8 cells to produce IF-
(272 273). IF-y can act either alone or synergistically with IF-al3 to suppress the
growth of hematopoietic stem cells (250 269). Therefore, the loss of IF-yproducing
TCR-y8 cells may decrease the severity of hematopoietic suppression resulting in the
increased survival of LCMV -infected TCR-y8 knockout mice.
In our final experiments, we sought to determne the mechanism by which
CD8+TCR-al3+asialo-GMl+ T cells prevent allogeneic bone marow engraftment. T cells
can destroy allogeneic bone marow cells through several mechanisms, including the
release of perforin, granzyme, or TNF-a, as well as by activating the Fas-FasL pathway
(44,45). Utilizing knockout mice that lacked functional Fas, FasL or perforin, we
observed that LCMV infection at the time of transplantation resulted in the lack 
allogeneic bone marow engraftment in all three groups of knockout mice. Furthermore
the vast majority of infected mice died soon after transplantation, suggesting that neither
the Fas/FasL pathway nor the release of perforin is the sole mechanism by which
CD8+TCR-al3+asialo-GMl+ T cells prevent allogeneic bone marow engraftment in
LCMV-infected mice. Further studies wil be necessary in order to determne whether
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granzyme or TNF-a is involved in LCMV -induced abrogation of allogeneic bone marow
engraftment.
Recently, it has been documented that mice conditioned with busulfan and treated
with anti-CD154 mAb , CTLA4-Ig, and a bone marow allograft lose that graft (but do not
die) if infected with LCMV (274). In that report, the mechanism of allogeneic stem cell
graft failure was not identified, but evidence was presented to suggest that both CD4+ and
CD8+ T cells were important and the authors hypothesized that the mechanism was
dependent on dendritic cells. In contrast, we clearly demonstrate that CD8+TCR-
al3+asialo-GMl+ T cells are involved in the rejection of allogeneic bone marow grafts.
The survival of mice treated with busulfan, in contrast to the death of mice treated with
sublethal irradiation, may be due to the differential effects of busulfan (a hematopoietic
stem cell selective toxin) versus irradiation (generalized toxin). Alternatively, the
different mechanisms involved in graft rejection between these two systems may induce
distinct responses with regards to cytokine release and/or cellular activation.
The discovery that CD8+TCR -al3 + asialo-GM I + T cells prevent the engraftment of
allogeneic bone marow raises two interesting questions. The first is how our
conditioning regimen of irradiation and anti-CDl54 mAb tolerizes these alloreactive T
cells , thus allowing allogeneic bone marow engraftment in uninfected mice. The second
question is how does LCMV infection overrde tolerance induction and activate the
alloreactive T cells.
In previous experiments, our laboratory has documented the complete deletion of
peripheral alloreactive CD8+ T cells after treatment with DST and anti-CDl54 mAb
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(120). These experiments were performed using splenocytes as DST. In a similar manner
one would expect that in these experiments injected donor bone marow cells would act
as DST and induce the complete deletion of alloreactive CD8+ T cells.
Recently however, we have discovered that bone marow, when used as DST
does not induce the complete deletion of peripheral alloreactive T cells (E. Seung-
unpublished observations). In a preliminary experiment, bone marow and anti-CDl54
mAb deleted -50% of the peripheral alloreactive T cells. Therefore, allogeneic bone
marow and anti-CD154 mAb does not cause the complete deletion of alloreactive
CD8+TCR-al3+asialo-GMl+ T cells. The question remains , what happens to the -50% of
peripheral alloreactive T cells that persist in mice given anti-CDl54 mAb and an
allogeneic bone marow transplant.
One possibility is that the remaining T cells are eliminated when recipient mice
receive 6 Gy of irradiation. In our experiments, treatment of C57BL/6 mice with 6 Gy
reduced femoral and splenic cellularty by 50-60%. Therefore, it is possible that half of
the all ore active T cells are eliminated after irradiation and the other half are deleted
following exposure to anti-CD154 mAb and allogeneic bone marow.
Alternatively, the alloreactive T cells that remain following irradiation may be
tolerized following exposure to allogeneic bone marow and anti-CDl54 mAb. Exposure
of alloantigen to host T cells (Signal I) under conditions where CDl54 can not interact
with its receptor, CD40 (Signal 2) can render allo-specific T cells anergic , while all other
T cells would remain unaffected (115).
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A second question that needs to be addressed is how do alloreactive T cells
become activated following LCMV infection. As mentioned above, half of the
alloreactive T cells in uninfected mice wil be destroyed following irradiation , and the
other half are most likely deleted following exposure to donor bone marow and anti-
CDl54 mAb. It is unlikely that LCMV infection interferes with the irradiation-induced
elimination of alloreactive T cells. Therefore, the real question is how does LCMV
prevent the deletion of alloreactive T cells caused by exposure to anti-CDl54 mAb and
allogeneic bone marow.
Previously, we have demonstrated the complete deletion of peripheral alloreactive
CD8+ T cells after treatment with DST and anti-CDl54 mAb (120). Additionally, we
have shown that LCMV infection at the time of tolerization prevented this deletion (275).
In fact, LCMV infection caused an increase in the levels of alloreactive CD8+ T cells.
Preventing the induction of peripheral clonal deletion and tolerance has also been
observed in mice treated with LPS (276-278), Poly I:C , or LCMV at the time of tolerance
induction (278). In the expeIiments presented here, both Poly I:C and LCMV were able
to prevent the engraftment of allogeneic bone marow, confirmng that Poly I:C and
LCMV are able to overcome the induction of tolerance. However, the mechanism by
which viruses, Poly I:C and LPS are able to overcome tolerance induction is stil
unkown.
One likely candidate for the ability of LPS, Poly I:C or viruses to overcome
tolerance induction are cytokines. Some of the redundant cytokine pathways that may be
involved are IL- l, IL- , IL- , TNF and IF-y (277 279). In one study, the prevention of
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superantigen-induced deletion by LPS was associated with the production of TNF-a
(277). The role of TNF-a or IF-y is particularly intriguing as TNF-a and IFN-y can
inhibit hematopoietic progenitor cell growth (254). IF-y can also act synergistically
with IF-al3 to suppress hematopoietic stem cell growth (250). Therefore, these two
cytokines could potentially playa role in both overcoming tolerance induction and in
LCMV -induced death. However, IFN-y is not involved in overcoming tolerance
induction in our system, as pretreatment with anti-IFN-y mAb did not prevent allograft
rejection induced by LCMV. In contrast, IF-y likely plays a role, along with IF-al3, in
LCMV -induced aplasia as pretreatment of LCMV -infected mice with anti-IF-y mAb
prevented LCMV -induced death. Additional experiments wil be necessary in order to
determne which cytokines , if any, are involved in preventing tolerance induction in
LCMV-infected mice treated with sublethal irradiation and anti-CDl54 mAb.
Recently, the role of dendrtic cells in the ability of viruses to overcome tolerance
induction has been investigated. Dendrtic cells can be stimulated by varous cytokines
(IL- , TNF-a and IF-al3), LPS , Poly I:C or soluble CD154 (280 281). Dendritic cell
stimulation leads to the upregulation of MHC class II molecules and costimulatory
molecules (CD80, CD86 and CD54) (282-284) as well as the release of several cytokines
(TNF-a, IL- , IL- , IL- 12) (283-285). Following activation and maturation, dendritic
cells migrate to the draining lymph nodes, and acquire the capacity to produce IL-
(286). CD40-CD154 interactions are critical for dendritic cell activation, as CD40
ligation is suffcient for dendrtic cell maturation (284), and to enable dendritic cells to
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prime CD8+ T cells (287). Furthermore , when CD40-CD154 interactions are blocked
dendrtic cells fail to mature, (288) are unable to localize to draining lymph nodes (289)
and show decreased survival (290).
In the last few years, it has also been documented that LCMV infection can
activate dendrtic cells in the absence of CD40-CD154 interaction (291). Dendritic cells
isolated from CD40 knockout mice 6 days after LCMV infection expressed upregulated
CD80 and CD86 surface expression. Therefore, CD80 and CD86 surface expression on
LCMV -activated dendritic cells would be capable of activating the alloreactive T cells in
our LCMV -infected mice treated with co stimulation blockade.
The mechanism by which LCMV infection activates dendritic cells is currently
unkown. One possibilty is IF-al3, as LCMV infection greatly increases the production
of IF-al3, and this cytokine is capable of activating dendrtic cells (280). Recent
experiments by Ruedl et al. however, have shown that either CD4+ or CD8+ T cells can
activate dendrtic cells in LCMV-infected mice (291). Although unsuccessful in
discovering the mediator by which CD8+ T cells activate dendritic cells, they have
eliminated several molecules and cytokines including: CD28, CD154, TRACE, TNF
IL- , IL- , IL- , IL- , IF-al3 and IF-y (291). The cytokine or factor involved is
therefore, not a commonly known activator of dendritic cells, and may even be a
molecule that has not yet been discovered.
. Although LCMV -induced activation of dendritic cells is one method of activating
the alloreactive T cells in our LCMV-infected mice given sublethal irradiation and
costimulation blockade, CD4+ T cell help may also be involved. Normally, anti-CDl54
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mAb would prevent the activation of CD4+ T cells by blocking the CD40-CD154
interaction. However, in LCMV-infected CDl54 knockout mice, CD4+ T cells can stil
produce IF-y, suggesting that these cells are being activated in a CD40-independent
manner. This CD4-CD154 independent mechanism of dendrtic cell activation was soon
solved with the discovery of TRANCE (TNF-related activation-induced cytokine)
(292,293). Blocking the TRANCE- TRACE- interaction completely prevented the
production of IF-y from CD4+ T cells isolated from LCMV-infected CD40 deficient
mice (294), suggesting that the TRANCE pathway is capable of activating CD4+ T cells
in the absence of CD40-CD154 interactions.
Therefore, there are two distinct pathways that could lead to LCMV-induced
activation of dendritic cells, which in turn activate alloreactive T cells. One pathway
involves the activation of CD4+ T cells through the TRACE pathway, and the second
pathway involves the activation of CD8+ T cells by an unkown mechanism. In our
model of LCMV -induced abrogation of tolerance CD4+ T cells are not necessary.
Allograft rejection occurred in LCMV -infected CD4 knockout mice, suggesting
therefore, at least with our conditioning regimen, that CD8+ T cells are suffcient to
induce dendritic cell activation.
Our working model of how sublethal irradiation and anti-CDl54 mAb induces
hematopoietic chimerism and donor-specific tolerance is presented in Figure 10.
Treatment of C57BL/6 mice with 6 Gy of irradiation has two effects. First, it destroys
some of the host bone marow cells , thus creating space for injected donor-derived bone
marow cells to engraft and expand. Second, irradiation deletes a portion of the peripheral
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alloreactive T cells capable of destroying the injected donor bone marrow. Following
irradiation, donor bone marrow cells and anti-CDl54 mAb are injected into recipients.
These injections expose the remaining host alloreactive T cells to donor alloantigen
(Signal 1) under conditions where CD154 is unable to interact with its receptor, CD40
(Signal 2). As a result, alloreactive T cells receive Signal I without receiving Signal 2
and are deleted. With the complete deletion of host alloreactive T cells, donor bone
marow is not destroyed by alloreactive CD8+TCR-al3+asialo-GM1+ T cells. Stem cells in
the injected donor bone marow are therefore free to localize to the host marow where
space for their engraftment and expansion has been provided by irradiation. Donor
dendrtic cell precursors then migrate from the marow to engraft in the thymus, where
they develop into thymc dendrtic cells and mediate negative selection of developing
donor-reactive host T cells. The continued presence of both donor and host origin
dendrtic cells in the thymus ensures that both donor-reactive and host-reactive T cells are
continually deleted in the thymus by negative selection , and as a result, permanent donor-
specific state of central tolerance is obtained.
Figure 11 depicts our working model of how LCMV infection at the time of
transplantation prevents the engraftment of allogeneic bone marrow and causes host
death in recipients treated with sublethal irradiation and co stimulation blockade. Initially,
as in uninfected recipients (Figure 10), mice are treated with 6 Gy irradiation, creating
space in the donor bone marow and removing some of the peripheral alloreactive T cells.
Next, the remaining peripheral alloreactive T cells are exposed to a combination of donor
bone marow, anti-CDl54 mAb, and an LCMV infection. As was the case with
.. '
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uninfected mice, alloreactive T cells receIve Signal 1 (alloantigeh) while unable to
receive Signal 2 (anti-CD154 mAb). In this case however, LCMV infection causes the
activation and upregulation of CD80 and CD86 on dendritic cells, possibly through
signals mediated by CD8+ T cells despite blockade of CD40-CD154 interactions.
Activated dendrtic cells can therefore display alloantigen, as well as costimulatory
molecules such as CD80 and CD86 , to induce the activation of alloreactive CD8+TCR-
al3+asialo-GMI + T cells. This stimulation of alloreactive T cells by activated dendrtic
cells prevents the alloreactive T cells from being deleted. As a result, alloreactive
CD8+TCR-al3+asialo-GMl+ T cells are available to recognize and destroy the injected
donor bone marow cells , thus preventing the establishment of hematopoietic chimerism.
Furthermore , the activation of alloreactive T cells induces the release of cytokines, such
as IF-yand possibly TNF-a. These cytokines then act in combination with LCMV-
induced IF-al3 to initiate a massive aplasia of hematopoietic stem cells , which results in
the death of LCMV-infected mice that receive costimulation blockade and a normally
sublethal dose of irradiation.
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Legend Figure 10: This figure schematically depicts our working model of how
sublethal irradiation and co stimulation blockade induces hematopoietic chimerism and
donor-specific tolerance in C57BL/6 mice.
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Legend Figure 11: This figure schematically depicts our working model of how
an LCMV infection at the time of bone marow transplantation prevents the engraftment
of allogeneic bone marow and causes host death in C57BU6 recipients treated with
sublethal irradiation and costimulation blockade.
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In summary, we have documented that a conditioning regimen of 6 Gy irradiation
anti-CDl54 mAb and BALB/c allogeneic bone marow can create stable hematopoietic
chimerism and donor-specific tolerance in C57BL/6 recipients. The induction of
tolerance and chimerism in our hematopoietic chimeras was extremely stable two weeks
after transplantation, as LCMV infection at this time point did not prevent the
maintenance of chimerism or tolerance. The recovery of anti-viral immunity in chimeric
mice was slightly delayed, as 7 weeks of recovery after transplantation was necessary to
recover the abilty to clear an LCMV infection.
As opposed to their maintenance, the induction of tolerance and chimerism was
extremely vulnerable in our recipient mice treated with costimulation blockade and
sublethal irradiation. LCMV infection on the day of transplantation prevented the
engraftment of allogeneic bone marow. Furthermore, these mice succumbed to aplasia-
induced death 2-3 weeks after transplantation. We have documented that the mediator of
graft rejection is a CD8+TCR-al3+asialo-GMl+ T cell and the mediator of death is the
host response to IF-al3. It is important to note that both graft loss and a fatal outcome
occurred after challenge with a virus that is usually non-cytopathic. It is of concern that
more virulent agents might have similar adverse consequences in the context of less
strngent conditioning or at later time points after bone marow transplantation. Clinical
application of stem cell transplantation protocols based on co stimulation blockade and
tolerance induction may therefore require initial patient isolation to facilitate the
procedure and to protect recipients.
:' '
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FUTURE DIRECTIONS
In this thesis work we have discovered that two different mechanisms are
involved in LCMV infection preventing the engraftment of allogeneic bone marow and
causing death in sublethally irradiated recipients treated with costimulation blockade. We
provide evidence that host response to IF -al3 and IF -
'1 are involved in LCMV -induced
aplasia, while alloreacti ve CD8+TCR -al3 + asialo-GM I + cells are the mediator of
allograft rejection. However, the experiments performed in this thesis leave many
unanswered questions that require additional research. First, what is the mechanism by
which IF-al3 in LCMV -infected mice induces aplasia. Second, how do alloreactive
CD8+TCR-al3+asialo-GMl+ T cells become activated and reject the allogeneic marow
graft. Third, what is the role of cytokines in this process. Fourth , what is the potential role
of virus-specific CD8+ T cells that cross-react with alloantigen that, following virus
infection, become memory alloreactive CD8+ T cells.
Although we have clearly shown that host IF-al3 receptor expression is
necessary for LCMV -induced aplasia and death, we have not discovered what other
cytokines may be involved in this process. Cytokines such as IF-y and TNF-a have
been shown to suppress hematopoietic stem cell growth (254). Although we have
evidence that IF-y is involved, we do not know its exact role in death, and the
involvement of TNF-a has yet to be determned. Many viral infections can impair
hematopoiesis and induce bone marow failure in stem cell transplant recipients treated
with conventional procedures; these include Epstein-Barr virus (295), cytomegalovirus
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(296 297), human herpesvirus 6 and 7 (298 299) and human immunodeficiency virus
(300,301) among others. The ability of each of these viruses to induce IF-al3, IFN-
and TNF-a may be a common factor in the ability of these viruses to impair
hematopoiesis and cause graft failure. Our finding, that LCMV can induce hematopoietic
aplasia and death even in recipients of sublethal irradiation is of concern and suggests
that these viruses may stil be problematic even in newer sublethal conditioning
regimens. Therefore, it would be of interest to know the exact relationship between the
viral infections associated with stem cell therapy and their corresponding cytokine
production profiles. With this knowledge, clinicians could take appropriate measures to
prevent hematopoietic suppression and aplasia from becoming life-threatening
complications after stem cell transplantation using sublethal conditioning and
costimulation blockade.
Another area of future research could be directed at the alloreactive CD8+TCR-
al3+asialo-GMI + T cell population that induces allograft rejection in our model.
Interestingly, this population is capable of causing allograft rejection immediately after
receiving 6 Gy of irradiation, suggesting that this population of T cells is radio-resistant.
If these CD8+ T cells are radioresistant, it would be of interest to lear whether they
become activated and expand in order to destroy the donor allogeneic bone marow , or
whether their existing numbers in the periphery are suffcient for allograft rejection. Our
studies suggest that this alloreactive response is dose-dependent, as 200 millon donor
allogeneic bone marow cells induced engraftment in LCMV-infected mice. Therefore, it
seems likely that this population of T cells does not expand, but rather is capable of
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causing allograft rejection without expansion. Future research would help to further our
understanding of these alloreactive radioresistant T cells. This research could ultimately
help clinicians to recover T cell immunity as quickly as possible in patients who receive
myeloablative therapies, and thus help to reduce the period of risk of infection that
typically follows stem cell transplantation.
Another area of future research involves the role of virus-activated CD8+ T cells
that are cross-reactive to alloantigen. Based on previous experiments in our laboratory
and the laboratory of our collaborator, Dr. Raymond Welsh, it appears that virus-
activated CD8+ T cells may express cross-reactivity to alloantigens, and memory
alloreactive T cells could be generated by virus infection. Memory T cells are extremely
hard to tolerize using a DST and anti-CDl54 mAb protocol (Dr. Markees , personal
communications). It would be interesting to see whether LCMV-immune mice could be
tolerized using our method of sublethal irradiation, anti-CDl54 mAb and allogeneic bone
marow; paricularly, the ability of a second cross-reactive virus-infection at the time of
transplantation to cause allograft rejection and death in LCMV -immune mice. Although
we have discovered that a primary LCMV immune response can cause allograft rejection
and death in our sublethally irradiated mice, we do not know the results of a memory
LCMV immune response at the time of transplantation. Understanding the role 
memory T cells in tolerance induction, allograft rejection and death is imperative if stem
cell transplantation therapies are to be safe for patients with latent infections such as
CMV.
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